

## VOLATOLOMICS

Larry J Kricka, Joesph R Wiencek, and Paolo Fortina  
 (IFCC Emerging Technology Division)

### INTRODUCTION

This IFCC Emerging Technology Division (ETD) is dedicated to providing current awareness for emerging technologies likely to have important clinical diagnostic applications in the near future. One of those technologies is volatolomics (breathomics) (*i.e.*, breath analysis).

This web page will provide a regularly updated perspective on the emerging clinical diagnostic applications of volatolomics over the next 3 years.

Breath analysis is not new and already has a few, but very specific applications (*e.g.*, breath alcohol testing, hydrogen, carbon monoxide, oxygen, carbon dioxide, nitric oxide, and nitrous oxide testing, <sup>13</sup>carbon/<sup>12</sup>carbon-based tests)(<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990505/>).

The types of breath analysis can be subdivided into:

- a. Analysis of exogenous compounds, *e.g.*, ethanol, nitrous oxide (anesthesia), <sup>13</sup>carbon compounds.
- b. Analysis of specific endogenous compounds, *e.g.*, oxygen, carbon dioxide, nitric oxide.
- c. Analysis of mixtures of unidentified endogenous compounds (*e.g.*, Volatile Organic Compounds or VOCs) to provide a diagnostic signature.
- d. Analysis of exhaled particles.

Current work on volatolomics centers on finding diagnostic utility in the pattern of compounds (VOCs) in breath. Breath analysis is an attractive proposition because this type of testing is non-invasive, applicable to the point-of-care and offers the possibility of real-time clinical management.

Already, there are more than 10 companies focused on the clinical diagnostic applications of volatolomics employing diverse analytical technologies (breath analysis analyzers are sometimes known as “electronic noses”). The broad range of diagnostic applications under investigation and development ranges from breath glucose testing to testing for different types of cancer.

Breath analysis technologies are diverse and include different types of mass spectrometry [*e.g.*, gas isotope ratio mass spectrometry (GIRMS), selected ion flow tube mass spectrometry (SIFT-MS), field asymmetric ion-mobility spectrometry (FAIMS), secondary electro-spray ionization-MS], sensors and sensor arrays (*e.g.*, copper bromide-based sensor, colorimetric high dimensional sensor array), gas chromatography (*e.g.*, GC SAW). Further notable aspects of breath analysis technologies are the use of artificial intelligence, cloud-based analysis of data and analyzers that link to a smartphone.

The scope and content of this web page will include:

1. News items and opinion pieces from key researchers/opinion leaders about recent developments in the clinical diagnostic applications of volatolomics.
2. A directory of companies active in the clinical diagnostic applications of volatolomics.
3. Links to clinical trials involving volatolomic testing.
4. Details of analyzers and regulatory approvals of clinical diagnostic products based on volatolomic testing.
5. A literature survey updated quarterly designed to provide an educational resource and a snapshot of work since 2010.

Breath alcohol testing, and associated hand-held alcohol meters (breathalyzers), is now a mature sector of breath analysis, as is breath testing for oxygen, CO<sub>2</sub>, and nitrous oxide, and these will not be considered here in any detail.

The web page has been developed in conjunction with key researchers and companies active in clinical applications of breath analysis. A particular feature of this webpage will be regular updates based on feedback from our readers.

**Please send updates and comments to Larry Kricka:**  
**[kricka@pennmedicine.upenn.edu](mailto:kricka@pennmedicine.upenn.edu)**

## 1. VOLATOLOMICS AND BREATH ANALYSIS IN THE NEWS

### General

[http://www.menssanaresearch.com/news\\_Menssana.html](http://www.menssanaresearch.com/news_Menssana.html)  
<https://www.owlstonemedical.com/about/news/>  
<http://www.breathdiagnosticsinc.com/newsarticles/>  
<https://www.bedfont.com/news>  
<http://cairndiagnostics.com/news/>  
<https://www.fossiliontech.com/in-the-media/>  
<https://www.newenglandbreath.com/videos>  
[www.pulmostics.com](http://www.pulmostics.com)

### Clinical

Breath Biopsy in the area of IPF:

<https://www.owlstonemedical.com/about/news/2018/jan/25/breath-biopsy-wins-global-ipf-catalyst-challenge/>

Phase II Respiratory Disease Clinical Trials for a novel drug for COPD:

<https://www.owlstonemedical.com/about/news/2017/nov/27/GSK-breath-biopsy-clinical-trial/>

Breath Biopsy to study disease drivers in Asthma and COPD:

<https://www.owlstonemedical.com/about/news/2018/apr/9/owlstone-medical-provides-services-to-astrazeneca/>

Mayo Clinic Laboratories Announce Collaboration to Develop New Diagnostic Test That Detects Lung Cancer Using Patients' Exhaled Breath:

<https://news.mayocliniclabs.com/2019/03/26/breath-diagnostics-mayo-clinic-laboratories-announce-collaboration-to-develop-new-diagnostic-test-that-detects-lung-cancer-using-patients-exhaled-breath/?LinkId=65319564>

## Blogs

<https://www.owlstonemedical.com/about/blog/>

## Webinars

[https://www.owlstonemedical.com/download/direct-breath-biopsy-webinar/?utm\\_source=various-zone-none&utm\\_medium=breath\\_biopsy\\_email&utm\\_campaign=00507-products-services-snippet-various-breath\\_biopsy\\_email-zone-none-20180221&mkt\\_tok=eyJpIjoiT0Rkak5qUm1NRFZrWIRkbSlInQiOilxbVU3ZGZWV1RHVmNGbHJ0RjdFUkxZbTRxTkFac0VDTzZWZ1pXdG9HUzRUVVY3a1JxbVozdZdnZlI4R1RZNThqc1RrUG41TE1KZWdubXvhOWxzNDhMRnVLalQ1S25TdU1BVXIEWDkwcmViOEkxS0ZxVFwvODdGR0hRWHJ6MU10QzgjfQ%3D%3D](https://www.owlstonemedical.com/download/direct-breath-biopsy-webinar/?utm_source=various-zone-none&utm_medium=breath_biopsy_email&utm_campaign=00507-products-services-snippet-various-breath_biopsy_email-zone-none-20180221&mkt_tok=eyJpIjoiT0Rkak5qUm1NRFZrWIRkbSlInQiOilxbVU3ZGZWV1RHVmNGbHJ0RjdFUkxZbTRxTkFac0VDTzZWZ1pXdG9HUzRUVVY3a1JxbVozdZdnZlI4R1RZNThqc1RrUG41TE1KZWdubXvhOWxzNDhMRnVLalQ1S25TdU1BVXIEWDkwcmViOEkxS0ZxVFwvODdGR0hRWHJ6MU10QzgjfQ%3D%3D)

## 2. A-Z DIRECTORY OF COMPANIES ACTIVE IN THE CLINICAL DIAGNOSTIC APPLICATIONS OF VOLATOLOMICS (BREATH ANALYSIS)

**Advanced Breath Diagnostics, Inc.** – see Cairn Diagnostics (<http://cairndiagnostics.com/>)  
**Applied Nanodetectors Limited** ([www.applied-nanodetectors.com](http://www.applied-nanodetectors.com))  
**Bedfont Scientific** ([www.bedfont.com](http://www.bedfont.com))  
**BreathDX** (<https://www.breathdx.com/about/>)  
**Breath Diagnostics Inc** ([www.breathdiagnosticsinc.com](http://www.breathdiagnosticsinc.com))  
**Breathtec Biomedical Inc** ([breathtecbiomedical.com](http://breathtecbiomedical.com))  
**Cairn Diagnostics** ([http://cairndiagnostics.com/](http://cairndiagnostics.com))  
**Circassia AB** (<http://www.niox.com>)  
**Fossil Ion Technology S.L.** ([www.fossiliontech.com](http://www.fossiliontech.com))  
**G.A.S. Gesellschaft für analytische Sensorsysteme mbH BioMedizin Zentrum Dortmund** (<http://www.gas-dortmund.de>)  
**Menssana Research Inc** ([www.menssanaresearch.com](http://www.menssanaresearch.com))  
**New England Breath Technologies Inc** ([https://www.newenglandbreath.com/](https://www.newenglandbreath.com))  
**Owlstone Medical Inc** ([https://www.owlstonemedical.com](http://www.owlstonemedical.com))  
**Pulmostics Inc** ([www.pulmostics.com](http://www.pulmostics.com))  
**Syft Technologies** ([https://www.syft.com/](https://www.syft.com))

See also: <https://www.nanalyze.com/2018/03/9-breath-diagnostics-companies/>

## 3. CLINICAL TRIALS

An analysis of clinical trial data from <https://clinicaltrials.gov/> between 1997 and 2017 (517 trials that have used or are using some kind of breath analysis) is available from Owlstone Medical at:

[https://www.owlstonemedical.com/about/blog/2017/sep/14/breath-analysis-clinical-trials/?mkt\\_tok=eyJpIjoiWmpCbU5XWmpaREZrTTJNMCIsInQiOiJINnk4K0xqbTV4Z1M2eUI1b0RDaXZsUHZKaVwvDRZZGxXaEtVVHYrMW1Ralc1OGx3dXJNMIIUMU5IQ0YwMTNDYXRNGh6ZkU4MHZNV3N2c2xNQVU4YThENzdwSzV1akNIUktMZHNMVlwvbkhFU29mY2pcL05QM0xHSUZwTGISd2IHMCJ9](https://www.owlstonemedical.com/about/blog/2017/sep/14/breath-analysis-clinical-trials/?mkt_tok=eyJpIjoiWmpCbU5XWmpaREZrTTJNMCIsInQiOiJINnk4K0xqbTV4Z1M2eUI1b0RDaXZsUHZKaVwvDRZZGxXaEtVVHYrMW1Ralc1OGx3dXJNMIIUMU5IQ0YwMTNDYXRNGh6ZkU4MHZNV3N2c2xNQVU4YThENzdwSzV1akNIUktMZHNMVlwvbkhFU29mY2pcL05QM0xHSUZwTGISd2IHMCJ9)  
 (accessed SAT March 2)

#### 4. ANALYZERS AND REGULATORY APPROVALS

Listed below is the current range of clinical breath analysis products with information on regulatory approvals (FDA, CE) where relevant.

##### **Applied Nanodetectors Limited**

**Headquarters:** Enfield Middlesex, UK

**Website:** <http://www.applied-nanodetectors.com/wordpress/breath-analysis/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
-	Sensor array platform that can be configured and can detect multiple species.

##### **Bedfont Scientific**

**Headquarters:** Harrietsham, Maidstone ME17 1JA, UK

**Website:** <https://www.bedfont.com/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
EC50 ToxCO+	Electrochemical sensor-based breath CO monitor. <i>FDA approved</i>
GastroCH <sub>4</sub> ECK®	Portable breath methane, hydrogen and oxygen monitor to aid in the detection of gastrointestinal disorders.
Gastrolyzer®	Hydrogen and methane breath monitors to help detect gastrointestinal disorders.
iCO Smokerlyzer®	Breath CO monitor for a smartphone/tablet to track your “quit smoking” progress anytime, anywhere.
Micro+™	Breath (CO) monitors to aid smoking cessation.
NOBreath®	Fractional exhaled Nitric Oxide (FeNO) breath monitor to help improve asthma management.
piCO™	Breath carbon monoxide (CO) monitor to help stop smoking.

piCObaby™	Breath CO monitoring for pregnant women to help them stop smoking.
Smokerlyzer®	Breath CO monitor for smoking cessation.
ToxCO®	Non-invasively screening for CO poisoning through breath and ambient air testing.

**BreathDX****Headquarters:** UK**Website:** <https://www.breathdx.com/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
AmBeR®	Non-invasive breath ammonia monitoring system for home and hospital use.
AmBeR® Clinical	Utilized for clinical studies where large volumes of patients and sampling regimens are required.

**Breath Diagnostics Inc.****Headquarters:** Louisville, KY, USA**Website:** <http://www.breathdiagnosticsinc.com/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
OneBreath	A breath sample (one normal breath into a 1 L non-reactive bag) is promptly evacuated across a silicon microreactor chip that selectively and irreversibly captures exhaled carbonyl compounds produced as a result of cancer metabolism. The small microreactor volume effectively concentrates the carbonyl compounds by 10,000-fold (other components in the breath pass through the microreactor). Captured carbonyls then are eluted and analyzed using mass spectrometry (MS).

**Algernon Pharmaceuticals formerly known as “Breathtec Biomedical, Inc”****Headquarters:** Vancouver, BC, Canada**Website:** <https://algernonpharmaceuticals.com/breathtec-biomedical-is-now-algernon-pharmaceuticals/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
FAIMS Breathalyzer Device	In development - non-invasive, portable hand-held device to be used by clinician's in the office, clinic or hospital setting, or by agents screening for infectious diseases at national border entry points that provides early detection of, e.g., lung cancer, respiratory diseases, infectious diseases, diabetes, liver disease.

**Cairn Diagnostics****Headquarters:** Brentwood, TN, USA

**Website:** <https://cairndiagnostics.com/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
<sup>13</sup> C-Spirulina Gastric Emptying Breath Test (GEBT)	Breath samples, collected periodically in capped glass tubes before and after test meal administration, are returned to a central laboratory for analysis by gas isotope ratio mass spectrometry (GIRMS) to determine the ratio of <sup>13</sup> CO <sub>2</sub> to <sup>12</sup> CO <sub>2</sub> in each sample.

*FDA approved*

#### **Circassia**

**Headquarters:** (The Oxford Science Park, Oxford, UK; Morrisville, NC, USA; Uppsala, Sweden)

**Website:** <https://www.circassia.com/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
---------------------------	---------------------------

NIOX MINO®	Point-of-care medical device for measuring fractional exhaled nitric oxide (FeNO), thus offering personalized asthma management.
------------	--

*FDA approved and CE-marked*

#### **Fossil Ion Technology S.L.**

**Headquarters:** Malaga, Spain

**Website:** <https://www.fossiliontech.com/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
---------------------------	---------------------------

SUPER SESI	Online MS analysis of low volatility metabolites in breath using secondary electro-spray ionization. Measure up to 2000 species in one exhalation.
------------	--

#### **Fujitsu Laboratories Ltd.**

**Headquarters:** Kawasaki, Japan

**Website:** <http://www.fujitsu.com/jp/group/labs/en/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
---------------------------	---------------------------

(prototype)	Mobile copper bromide-based sensor that measures ammonia in breath.
-------------	---

#### **G.A.S. Gesellschaft für analytische Sensorsysteme mbH BioMedizin Zentrum**

**Headquarters:** Dortmund, Germany

**Website:** <https://www.bmz-do.de/de/unternehmensverzeichnis/unternehmensverzeichnis-/gas-gesellschaft-fuer-analytische-sensorsysteme-mbh.htm> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
BreathSpec™	Sampling via directly exhaling into the device and samples are introduced directly in a controlled manner into the gas chromatograph linked to an ion-mobility-spectrometer. Also, breath samples in standard disposable syringes can be analyzed using the <u>GC-IMS</u> equipped with a Luer-adaptor

**Menssana Research Inc.****Headquarters:** Newark, NJ, USA**Website:** <http://www.menssanaresearch.com/#> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
---------------------------	---------------------------

BreathLink™	Mobile point-of-care internet-connected system for the collection, concentration and analysis of VOCs in human breath. A person breathes into the instrument for two minutes and their breath VOCs are rapidly analyzed with a gas chromatograph (picomolar sensitivity; GC SAW). The encrypted information is uploaded through a cloud application to a central laboratory where the chromatogram is analyzed with proprietary algorithms and a report is sent back to the point-of-care within minutes.
-------------	---

*CE-marked*

BreathX	Fully integrated user-friendly automated analyzer (GC SAW) for collection, analysis, and interpretation of biomarkers in breath. Secure server applies algorithms and sends reports.
---------	--

Heartsbreath™	A non-invasive breath test for breath biomarkers that predict the probability of grade 3 rejection in heart transplant recipients who received their transplants in the preceding year.
---------------	---

*FDA Humanitarian Device exemption***Metabolomx****Headquarters:** Mountain View, CA, USA**Website:** <http://metabolomx.com/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
---------------------------	---------------------------

Breathsensor	An array of colored chemical indicators of diverse reactivities embedded in a nanoporous sol-gel matrix changes color in response to components in breath, creating a high dimensional and specific fingerprint.
--------------	--

**New England Breath Technologies, Inc.****Headquarters:** Springfield, MA, USA

**Website:** <https://www.breathhealth.net/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
GLUCAIR™ Diabetic Monitor	Detects breath acetone concentration and this has a very high correlation to blood glucose levels.
Illume™ Diabetes Screener	Assist in the identification of diabetes through a simple, non-fasting breath test. This non-invasive test is designed to provide an instant result that will help identify when a confirmatory blood test is warranted.

#### **Owlstone Medical, Inc.**

**Headquarters:** Science Park, Cambridge, UK

**Website:** [https://www.owlstonemedical.com/?utm\\_source=owlstone-keywords-zone-1&utm\\_medium=ga-search&utm\\_campaign=00435-corporate-brand-search-owlstone-keywords-ga-search-zone-1-20171214&gclid=CjwKCAiA8OjjBRB4EiwAMZe6y6cRJxt1g2fvxaffUjbOzMxCnO1pamMtnUwNg4WLtnoKKiCrN48ckhoCP5cQAvD\\_BwE](https://www.owlstonemedical.com/?utm_source=owlstone-keywords-zone-1&utm_medium=ga-search&utm_campaign=00435-corporate-brand-search-owlstone-keywords-ga-search-zone-1-20171214&gclid=CjwKCAiA8OjjBRB4EiwAMZe6y6cRJxt1g2fvxaffUjbOzMxCnO1pamMtnUwNg4WLtnoKKiCrN48ckhoCP5cQAvD_BwE) (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
Lonestar VOC Analyzer	A non-invasive, easy to use analyzer for the detection of disease biomarkers in clinical samples using Field Asymmetric Ion Mobility Spectrometry (FAIMS) technology.
ReCIVA® Breath Sampler	Device for reliable and reproducible capture of VOCs in breath samples.

*CE-marked*

#### **Pulmostics, Inc.**

**Headquarters:** Newbury Park, CA, USA

**Website:** <https://www.pulmostics.com/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
-	Integrated breath analysis systems.

#### **Syft Technologies**

**Headquarters:** Middleton, Christchurch, New Zealand

**Website:** <https://www.syft.com/> (Accessed March 1 2019)

<b>Product (Analyzer)</b>	<b>Description of Use</b>
Voice200ultra	Ion flow tube mass spectrometry platform for monitoring VOCs.

#### **5. LITERATURE BY TOPIC – DIAGNOSTIC APPLICATIONS (2010 onwards)**

The following literature provides an overview of the extent and diversity of research and development in the area of volatolomics (breath analysis). A key journal in this area is the Journal of Breath Research ([opscience.iop.org/journal/1752-7163](http://opscience.iop.org/journal/1752-7163)) that published its first issue in 2007. In addition, several companies maintain publication archives on their web sites – see:

[http://www.menssanaresearch.com/publications\\_Menssana.html](http://www.menssanaresearch.com/publications_Menssana.html);  
<http://www.breathdiagnosticsinc.com/technology/published-articles/>  
<http://cairndiagnostics.com/resources/>  
<http://www.niox.com/en-US/feno-asthma/publications/>  
<https://www.fossiliontech.com/publications/>  
<https://www.fossiliontech.com/patents/>  
<https://www.newenglandbreath.com/articles>  
[www.pulmostics.com](http://www.pulmostics.com)  
[https://www.syft.com/?s=&fwp\\_categories=media,publications,article](https://www.syft.com/?s=&fwp_categories=media,publications,article)

## 5.1. ANALYZERS, SENSORS AND METHODS

### 2019

Lin T, Lv X, Hu Z, Xu A, Feng. Semiconductor metal oxides as chemoresistive sensors for detecting volatile organic compounds. *Sensors (Basel)*. 2019;19(2):233. Available from: doi: 10.3390/s19020233.

### 2018

Motooka M, Uno S. Improvement in limit of detection of enzymatic biogas sensor utilizing chromatography paper for breath analysis. *Sensors (Basel)*. 2018;18(2):440. Available from: doi:10.3390/s18020440.

### 2016

Maniscalco M, Vitale C, Varella A, Molino A, Bianco A, Mazzarella G. Fractional exhaled nitric oxide-measuring devices: technology update. *Med Devices (Auckl)*. 2016;9:151–60. Available from: doi: 10.2147/MDER.S91201.

### 2014

Broza YY, Zuri L, Haick H. Combined volatolomics for monitoring of human body chemistry. *Sci Rep*. 2014;4: 4611. Available from: doi: 10.1038/srep04611.

Inyawilert K, Wisitsora-at A, Tuantranont A, Singjai P, Phanichphant S, Liewhiran C. Ultra-rapid VOCs sensors based on sparked-In<sub>2</sub>O<sub>3</sub> sensing films. *Sens Actuators B Chem*. 2014;192:745–54. Available from: doi.org/10.1016/j.snb.2013.11.064.

Wolf A, Baumbach JI, Kleber A, Maurer F, Maddula S, Favrod P, et al. Multi-capillary column-ion mobility spectrometer (MCC-IMS) breath analysis in ventilated rats: a model with the feasibility of long-term measurements. *J Breath Res*. 2014;8(1):016006. Available from: doi: 10.1088/1752-7155/8/1/016006.

### 2013

Zrodnikov Y, Zamuruyev K, Pedersen JD, et al. Design criteria for portable point-of-care breath analysis systems. In: 2013 Transducers and Eurosensors XXVII: The 17th

International Conference on Solid-State Sensors, Actuators and Microsystems, TRANSDUCERS and EUROSENSORS 2013:1629-32).

### **2012**

- Kapande KM, McConaghy LA, Douglas I, McKenna S, Hughes JL, McCance DR, et al. Comparative repeatability of two handheld fractional exhaled nitric oxide monitors. *Pediatr Pulmonol.* 2012;47(6):546–50. Available from: doi: 10.1002/ppul.21591.
- King J, Unterkofler K, Teschl G, Teschl S, Mochalski P, Koç H, et al. A modeling-based evaluation of isothermal rebreathing for breath gas analyses of highly soluble volatile organic compounds. *J Breath Res.* 2012;6(1):016005. Available from: doi: 10.1088/1752-7155/6/1/016005.

Takeno S, Noda N, Hirakawa K. Measurements of nasal fractional exhaled nitric oxide with a hand-held device in patients with allergic rhinitis: relation to cedar pollen dispersion and laser surgery. *Allergol Int.* 2012;61(1):93–100. Available from: doi: 10.2332/allergolint.11-OA-0318.

### **2011**

- Hunter GW, Xu JC, Biaggi-Labiosa AM, Laskowski D, Dutta PK, Mondal SP, et al. Smart sensor systems for human health breath monitoring applications. *J Breath Res.* 2011;5(3):037111. Available from: doi: 10.1088/1752-7155/5/3/037111.
- Hüttmann EM, Greulich T, Hattesohl A, Schmid S, Noeske S, Herr C, et al. Comparison of two devices and two breathing patterns for exhaled breath condensate sampling. *PLoS One.* 2011;6(11):e27467. Available from: doi: 10.1371/journal.pone.0027467.

### **2010**

- Antus B, Horvath I, Barta I. Assessment of exhaled nitric oxide by a new hand-held device. *Respir Med.* 2010;104(9):1377–80. Available from: doi: 10.1016/j.rmed.2010.06.005.

## **Artificial intelligence**

### **2015**

- Ligor T, Pater Ł, Buszewski B. Application of an artificial neural network model for selection of potential lung cancer biomarkers. *J Breath Res.* 2015;9(2):027106. Available from: doi: 10.1088/1752-7155/9/2/027106.

## **Electronic nose**

### **2016**

- Rocco R, Incalzi RA, Pennazza G, Santonico M, Pedone C, Bartoli IR, et al. BIONOTE e-nose technology may reduce false positives in lung cancer screening programmes. *Eur J Cardiothorac Surg.* 2016;49(4):1112–7. Available from: doi: 10.1093/ejcts/ezv328.

### **2015**

- Bikov A, Lázár Z, Horvath I. Established methodological issues in electronic nose research: how far are we from using these instruments in clinical settings of breath analysis? *J Breath Res.* 2015;9(3):034001. Available from: doi: 10.1088/1752-7155/9/3/034001.

de Vries R, Brinkman P, van der Schee MP, Fens N, Dijkers E, Bootsma SK, et al. Integration of electronic nose technology with spirometry: validation of a new approach for exhaled breath analysis. *J Breath Res.* 2015;9(4):046001. Available from: doi: 10.1088/1752-7155/9/4/046001.

Leopold JH, Bos LD, Sterk PJ, Schultz MJ, Fens N, Horvath I, et al. Comparison of classification methods in breath analysis by electronic nose. *J Breath Res.* 2015;9(4):046002. Available from: doi: 10.1088/1752-7155/9/4/046002.

McWilliams A, Beigi P, Srinidhi A, Lam S, MacAulay CE. Sex and smoking status effects on the early detection of early lung cancer in high-risk smokers using an electronic nose. *IEEE Trans Biomed Eng.* 2015;62(8):2044–54. Available from: doi: 10.1109/TBME.2015.2409092.

Seesaard T, Lorwongtragool P, Kerdcharoen T. Development of fabric-based chemical gas sensors for use as wearable electronic noses. *Sensors (Basel).* 2015;15(1):1885–1902. Available from: doi: 10.3390/s150101885.

Wilson AD. Advances in electronic-nose technologies for the detection of volatile biomarker metabolites in the human breath. *Metabolites.* 2015;5(1):140-63. Available from: doi: 10.3390/metabo5010140.

#### **2014**

Gromski PS, Correa E, Vaughan AA, Wedge DC, Turner ML, Goodacre R. A comparison of different chemometrics approaches for the robust classification of electronic nose data. *Anal Bioanal Chem.* 2014;406(29):7581–90. Available from: doi: 10.1007/s00216-014-8216-7.

#### **2013**

Fens N, van der Schee MP, Brinkman P, Sterk PJ. Exhaled breath analysis by electronic nose in airways disease. Established issues and key questions. *Clin Exp Allergy.* 2013;43(7):705–15. Available from: doi: 10.1111/cea.12052.

#### **2012**

Brinkman P, van der Schee M, Fens N, Pennazza G, Santonico M, D'Amico A, et al. Calibration of a (semi)-automatic measurement and control platform for centralized, simultaneous electronic nose (eNose) analyses in multi-centre trials. *Eur Respir J.* 2012;40(Suppl 56):P4307.

Mandon J, Höglund M, Merkus PJ, van Amsterdam J, Harren FJ, Cristescu SM. Exhaled nitric oxide monitoring by quantum cascade laser: comparison with chemiluminescent and electrochemical sensors. *J Biomed Opt.* 2012;17(1):017003. Available from: doi: 10.1117/1.JBO.17.1.017003.

Kumar B, Park YT, Castro M, Grunlan JC, Feller JF. Fine control of carbon nanotubes– polyelectrolyte sensors sensitivity by electrostatic layer by layer assembly (eLbL) for the detection of volatile organic compounds (VOC). *Talanta.* 2012;88:396–402. Available from: doi: 10.1016/j.talanta.2011.11.006.

Santonico M, Pennazza G, Capuano R, Falconi C, Vink TJ, Knobel HH, et al. Electronic noses calibration procedure in the context of a multicentre medical study. *Sens*

*Actuators B Chem.* 2012;173:555–61. Available from: doi.org/10.1016/j.snb.2012.07.042.

### 2011

Bikov A, Lazar Z, Schandl K, Antus BM, Losonczy G, Horvath I. Exercise changes volatiles in exhaled breath assessed by an electronic nose. *Acta Physiol Hung.* 2011;98(3):321–8. Available from: doi: 10.1556/APhysiol.98.2011.3.9.

### Immunoassay

#### 2015

Pleil JD, Angrish MM, Madden MC. Immunochemistry for high-throughput screening of human exhaled breath condensate (EBC) media: implementation of automated Quanterix SIMOA instrumentation. *J Breath Res.* 2015;9(4):047108. Available from: doi: 10.1088/1752-7155/9/4/047108.

### 2012

Nunez-Naveira L, Marinas-Pardo LA, Amor-Carro O, Montero-Martinez C. Determination of ELISA reproducibility to detect protein markers in exhaled breath condensate. *J Breath Res.* 2012;6(4):046003. Available from: doi: 10.1088/1752-7155/6/4/046003.

### Mass Spectrometry

#### 2018

Singh KD, Del Miguel GV, Gaugg MT, Ibañez AJ, Zenobi R, Kohler M, et al. Translating secondary electrospray ionization–high-resolution mass spectrometry to the clinical environment. *J Breath Res.* 2018;12(2):027113. Available from: doi: 10.1088/1752-7163/aa9ee3.

### 2016

Clara Leigh Feider, Natalia Elizondo, Livia S. Eberlin. Ambient ionization and FAIMS mass spectrometry for enhanced imaging of multiply charged molecular ions in biological tissues. *Anal Chem.* 2016;88(23):11533-41.

### 2014

David S, Patrik Š, Jens H, Beauchamp J. Mass spectrometry for real-time quantitative breath analysis. *J Breath Res.* 2014;8(2):027101. Available from: doi: 10.1088/1752-7155/8/2/027101.

### 2013

Bikov A, Paschalaki K, Logan-Sinclair R, Horváth I, Kharitonov SA, Barnes PJ, et al. Standardised exhaled breath collection for the measurement of exhaled volatile organic compounds by proton transfer reaction mass spectrometry. *BMC Pulm Med.* 2013;13:43. Available from: doi: 10.1186/1471-2466-13-43.

Kumar S, Huang J, Abbassi-Ghadi N, Španěl P, Smith D, Hanna GB. Selected ion flow tube mass spectrometry analysis of exhaled breath for volatile organic compound profiling of esophago-gastric cancer. *Anal Chem.* 2013;85(12):6121–8. Available from: doi: 10.1021/ac4010309.

Phillips M, Cataneo RN, Chaturvedi A, Kaplan PD, Libardoni M, Mundada M, et al. Detection of an extended human volatome with comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry. *PLoS One.* 2013;8(9):e75274.

Available from: doi: 10.1371/journal.pone.0075274.

Trefz P, Schmidt M, Oertel P, Obermeier J, Brock B, Kamysek S, et al. Continuous real time breath gas monitoring in the clinical environment by proton-transfer-reaction-time-of-flight-mass spectrometry. *Anal Chem*. 2013;85(21):10321–9. Available from: doi: 10.1021/ac402298v.

### **2012**

Janicka M, Kubica P, Kot-Wasik A, Kot J, Namieśnik J. Sensitive determination of isoprostanes in exhaled breath condensate samples with use of liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2012;893–894:144–9. Available from: doi: 10.1016/j.jchromb.2012.03.005.

### **2011**

Turner MA, Guallar-Hoyas C, Kent AL, Wilson ID, Thomas CLP. Comparison of metabolomic profiles obtained using chemical ionization and electron ionization MS in exhaled breath. *Bioanalysis*. 2011;3(24):2731–8. Available from: doi: 10.4155/bio.11.284.

### **Nanotechnology**

#### **2017**

Kim ID. How can nanotechnology be applied to sensors for breath analysis? *Nanomedicine (Lond)*. 2017;12(22):2695–7. Available from: doi: 10.2217/nmm-2017-0269.

Nakhleh MK, Amal H, Jeries R, Broza YY, Aboud M, Gharra A, et al. Diagnosis and classification of 17 diseases from 1404 subjects via pattern analysis of exhaled molecules. *ACS Nano*. 2017;11(1):112–25. Available from: doi: 10.1021/acsnano.6b04930.

Righettoni M, Amann A, Pratsinis SE. Breath analysis by nanostructured metal oxides as chemo-resistive gas sensors. *Mats Today*. 2015;18:163–71. Available from: doi.org/10.1016/j.mattod.2014.08.017.

### **2015**

Fernandes MP, Venkatesh S, Sudarshan BG. Early detection of lung cancer using nano-nose - A review. *Open Biomed Eng J*. 2015;9:228–33. Available from: doi: 10.2174/1874120701509010228.

### **2014**

Konvalina G, Haick H. Sensors for breath testing: From nanomaterials to comprehensive disease detection. *Acc Chem Res*. 2014;47(1):66–76. Available from: doi: 10.1021/ar400070m.

### **2011**

Gouma P1, Prasad A, Stanacevic S. A selective nanosensor device for exhaled breath analysis. *J Breath Res*. 2011;5(3):037110. Available from: doi: 10.1088/1752-7155/5/3/037110.

**2010**

Tisch U, Haick H. Arrays of chemisensitive monolayer capped metallic nanoparticles for diagnostic breath testing. *Rev Chem Eng.* 2010;26:171-9.  
doi: <https://doi.org/10.1515/revce.2010.009>.

**Surface-Enhanced Raman Scattering****2016**

Chen Y, Zhang Y, Pan F, Liu J, Wang K, Zhang C, et al. Breath analysis based on surface-enhanced raman scattering sensors distinguishes early and advanced gastric cancer patients from healthy persons. *ACS Nano.* 2016;10(9):8169–79.  
Available from: doi: 10.1021/acsnano.6b01441.

**2013**

Broza YY, Kremer R, Tisch U, Gevorkyan A, Shiban A, Best LA, et al. A nanomaterial-based breath test for short-term follow-up after lung tumor resection. *Nanomedicine.* 2013;9(1):15-21. Available from: doi: 10.1016/j.nano.2012.07.009.

**5.2. APPLICATIONS****Acetone Testing****2017**

Ruzsányi V, Kalapos MP. Breath acetone as a potential marker in clinical practice. *J Breath Res.* 2017;11(2):024002. Available from: doi: 10.1088/1752-7163/aa66d3.

**2012**

King J, Kupferthaler A, Frauscher B, Hackner H, Unterkofler K, Teschl G, et al. Measurement of endogenous acetone and isoprene in exhaled breath during sleep. *Physiol Meas.* 2012;33(3):413–28. Available from: doi: 10.1088/0967-3334/33/3/413.

**Allergy****2012**

La Grutta S, Ferrante G, Malizia V, Cibella F, Viegi G. Environmental effects on fractional exhaled nitric oxide in allergic children. *J Allergy (Cairo).* 2012;2012:916926. Available from: doi: 10.1155/2012/916926.

**Animal Studies****2015**

Albrecht FW, Huppe T, Fink T, Maurer F, Wolf A, Wolf B, et al. Influence of the respirator on volatile organic compounds: an animal study in rats over 24 hours. *J Breath Res.* 2015;9(1):016007. Available from: doi: 10.1088/1752-7155/9/1/016007.

Fink T, Albrecht FW, Maurer F, Kleber A, Hüppe T, Schnauber K, et al. Exhalation pattern changes during fasting and low dose glucose treatment in rats. *Anal Bioanal Chem.* 2015;407(13):3763–73. Available from: doi: 10.1007/s00216-015-8602-9.

Fischer S, Trefz P, Bergmann A, Steffens M, Ziller M, Miekisch W, et al. Physiological variability in volatile organic compounds (VOCs) in exhaled breath and released from faeces due to nutrition and somatic growth in a standardized caprine animal model. *J Breath Res.* 2015;9(2):027108.

Hirotsu T, Sonoda H, Uozumi T, Shinden Y, Mimori K, Maehara Y, et al. A highly

accurate inclusive cancer screening test using *Caenorhabditis elegans* scent detection. *PLoS One*. 2015;10(3):e0118699. Available from: doi: 10.1371/journal.pone.0118699.

## Asthma

### 2017

Brinkman P, van de Pol MA, Gerritsen MG, Bos LD, Dekker T, Smids BS, et al. Exhaled breath profiles in the monitoring of loss of control and clinical recovery in asthma. *Clin Exp Allergy*. 2017;47(9):1159–69. Available from: doi: 10.1111/cea.12965.

### 2016

Bikov A, Horvath I. Methodological issues and possible clinical implications for exhaled breath condensate pH in asthma. *Curr Top Med Chem*. 2016;16(14):1550–60.

Lehtimäki L, Csonka P, Mäkinen E, Isojärvi J, Hovi SL, Ahovuo-Saloranta A. Predictive value of exhaled nitric oxide in the management of asthma: a systematic review. *Eur Respir J*. 2016;48(3):706–14. Available from: doi: 10.1183/13993003.00699-2016.

Van Vliet D, Smolinska A, Jobsis Q, Rosias PP, Muris JW, Dallinga JW, et al. Association between exhaled inflammatory markers and asthma control in children. *J Breath Res*. 2016;10(1):016014. Available from: doi: 10.1088/1752-7155/10/1/016014.

### 2015

Petsky HL, Kew KM, Turner C, Chang AB. Exhaled nitric oxide levels to guide treatment for adults with asthma. *Cochrane Database Syst Rev*. 2016;9:CD011440. Available from: doi: 10.1002/14651858.CD011440.pub2.

Ricciardolo FL, Sorbello V, Ciprandi G. FeNO as biomarker for asthma phenotyping and management. *Allergy Asthma Proc*. 2015;36(1):e1–8. Available from: doi: 10.2500/aap.2015.36.3805.

Thornadtsson A, Neerincx AH, Höglund M, Hugen C, Sint Nicolaas C, Harren FJ, et al. Extended NO analysis may improve personalized anti-inflammatory treatment in asthmatic children with intermediate FENO50. *J Breath Res*. 2015;9(4):047114. Available from: doi: 10.1088/1752-7155/9/4/047114.

Fens N, van der Sluijs KF, van de Pol MA, Dijkhuis A, Smids BS, van der Zee JS, et al. Electronic nose identifies bronchoalveolar lavage fluid eosinophils in asthma. *Am J Respir Crit Care Med*. 2015;191(9):1086–8. Available from: doi: 10.1164/rccm.201411-2010LE.

### 2014

Meyer N, Dallinga JW, Nuss SJ, Moonen EJ, van Berkel JJ, Akdis C, et al. Defining adult asthma endotypes by clinical features and patterns of volatile organic compounds in exhaled air. *Respir Res*. 2014;15:136. Available from: doi: 10.1186/s12931-014-0136-8.

Heijkenskjöld-Rentzhog C, Nordvall L, Janson C, Borres MP, Alving K, Malinovschi A. Alveolar and exhaled NO in relation to asthma characteristics - effects of correction for axial diffusion. *Allergy*. 2014;69(8):1102–11. Available from: doi:

10.1111/all.12430.

Smolinska A, Klaassen EM, Dallinga JW, van de Kant KD, Jobsis Q, Moonen EJ, et al. Profiling of volatile organic compounds in exhaled breath as a strategy to find early predictive signatures of asthma in children. *PLoS One*. 2014;9(4):e95668. Available from: doi: 10.1371/journal.pone.0095668.

### 2013

Carraro S, Giordano G, Piacentini G, Kantar A, Moser S, Cesca L, et al. Asymmetric dimethylarginine in exhaled breath condensate and serum of children with asthma. *Chest*. 2013;144(2):405–10. Available from: doi: 10.1378/chest.12-2379.

Carraro S, Giordano G, Reniero F, Carpi D, Stocchero M, Sterk PJ, et al. Asthma severity in childhood and metabolomic profiling of breath condensate. *Allergy*. 2013;68(1):110–7. Available from: doi: 10.1111/all.12063.

Gahleitner F, Guallar-Hoyas C, Beardsmore CS, Pandya HC and Thomas CP. Metabolomics pilot study to identify volatile organic compound markers of childhood asthma in exhaled breath. *Bioanalysis*. 2013;5(18):2239–47. Available from: doi: 10.4155/bio.13.184.

Högman M, Meriläinen P. Guidance for a personal target value of FENO in allergic asthma: case report and theoretical example. *Ups J Med Sci*. 2013;118(1):59–61. Available from: doi: 10.3109/03009734.2012.704433.

Ibrahim B, Marsden P, Morris J, Smith J, Nilsson M, Fowler SJ. Metabolomic analysis of exhaled breath condensate by NMR spectroscopy discriminates inflammatory phenotypes in asthma. *Allergy*. 2013;68:1050–6.

Robroeks CM, van Berkel JJ, Jobsis Q, van Schooten FJ, Dallinga JW, Wouters EF, et al. Exhaled volatile organic compounds predict exacerbations of childhood asthma in a 1-year prospective study. *Eur Respir J*. 2013;42(1):98–106. Available from: doi: 10.1183/09031936.00010712.

Syslova K, Bohmova A, Demirbag E, et al. Immunomagnetic molecular probe with UHPLC-MS/MS: a promising way for reliable bronchial asthma diagnostics based on quantification of cysteinyl leukotrienes. *J Pharm Biomed Anal*. 2013;81–82:108–17. Available from: doi: 10.1016/j.jpba.2013.03.026.

van der Schee MP, Palmary R, Cowan JO, Taylor DR. Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. *Clin Exp Allergy*. 2013;43(11):1217–25. Available from: doi: 10.1111/cea.12147.

Wagener AH, Yick CY, Brinkman P, van der Schee MP, Fens N, Sterk PJ. Toward composite molecular signatures in the phenotyping of asthma. *Ann Am Thorac Soc*. 2013;10:Suppl S197–S205. Available from: doi: 10.1513/AnnalsATS.201302-035AW.

### 2012

Almstrand AC, Josefson M, Bredberg A, Lausmaa J, Sjövall P, Larsson P, et al. TOF-SIMS analysis of exhaled particles from patients with asthma and healthy controls.

*Eur Respir J* 2012;39(1):59–66. Available from: doi: 10.1183/09031936.00195610.

Chladkova J, Senkerik M, Havlinova Z, Krcmová I, Chládek J. Alveolar concentration and bronchial flux of nitric oxide: two linear modeling methods evaluated in children and adolescents with allergic rhinitis and atopic asthma. *Pediatr Pulmonol*. 2012;47(11):1070–9. Available from: doi: 10.1002/ppul.22550.

Heijkenskjöld-Rentzhog C, Alving K, Kalm-Stephens P, Lundberg JO, Nordvall L, Malinovschi A. The fraction of NO in exhaled air and estimates of alveolar NO in adolescents with asthma: methodological aspects. *Pediatr Pulmonol*. 2012;47(10):941–9. Available from: doi: 10.1002/ppul.22556.

Mandon J, Hogman M, Merkus PJ, van Amsterdam J, Harren FJ, Cristescu SM. Exhaled nitric oxide monitoring by quantum cascade laser: comparison with chemiluminescent and electrochemical sensors. *J Biomed Opt*. 2012;17(1):017003. Available from: doi: 10.1117/1.JBO.17.1.017003.

Szeffler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, et al. Asthma outcomes: biomarkers. *J Allergy Clin Immunol*. 2012;129(3 Suppl):S9-23. Available from: doi: 10.1016/j.jaci.2011.12.979.

### 2011

Fens N, Roldaan AC, van der Schee MP, Boksem RJ, Zwinderman AH, Bel EH, et al. External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease. *Clin Exp Allergy*. 2011;41(10):1371–8. Available from: doi: 10.1111/j.1365-2222.2011.03800.x.

Högman M, Malinovschi A, Norbäck D, Janson C. Added value with extended NO analysis in atopy and asthma. *Clin Physiol Funct Imaging*. 2011;31(4):294–9.

Ibrahim B, Basanta M, Cadden P, Singh D, Douce D, Woodcock A, et al. Non-invasive phenotyping using exhaled volatile organic compounds in asthma. *Thorax*. 2011;66(9):804–9. Available from: doi: 10.1136/thx.2010.156695.

Liu L, Teague WG, Erzurum S, Fitzpatrick A, Mantri S, Dweik RA, et al. Determinants of exhaled breath condensate pH in a large population with asthma. *Chest*. 2011;139(2):328–36. Available from: doi: 10.1378/chest.10-0163.

Shorter JH, Nelson DD, McManus JB, Zahniser MS, Sama S, Milton DK. Clinical study of multiple breath biomarkers of asthma and COPD (NO, CO<sub>2</sub>, CO and N<sub>2</sub>O) by infrared laser spectroscopy. *J Breath Res*. 2011;5:037108. Available from: doi: 10.1088/1752-7155/5/3/037108.

### 2010

Antus B, Barta I, Kullmann T, Lazar Z, Valyon M, Horvath I, et al. Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: a longitudinal study. *Am J Respir Crit Care Med*. 2010;182(12):1492–7. Available from: doi: 10.1164/rccm.201003-0451OC.

Dallinga JW, Robroeks CM, van Berkel JJ, Moonen EJ, Godschalk RW, Jöbsis Q, et al. Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in

children. *Clin Exp Allergy*. 2010;40(1):68–76. Available from: doi: 10.1111/j.1365-2222.2009.03343.x.

Lazar Z, Cervenak L, Orosz M, Gálffy G, Komlósi ZI, Bikov A, et al. Adenosine triphosphate concentration of exhaled breath condensate in asthma. *Chest*. 2010;138(3):536–42. Available from: doi: 10.1378/chest.10-0085.

Lazar Z, Fens N, van der Maten J, van der Schee MP, Wagener AH, de Nijs SB, et al. Electronic nose breathprints are independent of acute changes in airway caliber in asthma. *Sensors (Basel)*. 2010;10(10):9127–38. Available from: doi: 10.3390/s101009127.

Mahut B, Trinquart L, Le Bourgeois M, Becquemin MH, Beydon N, Aubourg F, et al. Multicentre trial evaluating alveolar NO fraction as a marker of asthma control and severity. *Allergy*. 2010;65(5):36–44. Available from: doi: 10.1111/j.1398-9995.2009.02221.x.

Montuschi P, Santonico M, Mondino C, Pennazza G, Mantini G, Martinelli E, et al. Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. *Chest*. 2010;137(4):790–6. Available from: doi: 10.1378/chest.09-1836.

Robroeks CM, van Vliet D, Hendriks HJ, Dompeling E, Jöbsis Q. Feasibility of exhaled nitric oxide measurements at various flow rates in children with asthma. *Pediatr Allergy Immunol*. 2010;21:e222-8. Available from: doi: 10.1111/j.1399-3038.2009.00874.x.

## Cancer

### 2015

Hirotsu T, Sonoda H, Uozumi T, et al. A highly accurate inclusive cancer screening test using *Caenorhabditis elegans* scent detection. *PLoS One*. 2015;10(3):0118699. Available from: doi: 10.1371/journal.pone.0118699.

Schmidt K, Podmore I. Current challenges in volatile organic compounds analysis as potential biomarkers of cancer. *J Biomarker*. 2015;2015:981458. Available from: doi: 10.1155/2015/981458.

### 2014

Haick H, Broza YY, Mochalski P, Ruzsanyi V, Amann A. Assessment, origin, and implementation of breath volatile cancer markers. *Chem Soc Rev*. 2014;43(5):1423–49. Available from: doi: 10.1039/c3cs60329f.

### 2012

Buszewski B, Rudnicka J, Ligor T, Walczak M, Jezierski T, Amann A. Analytical and unconventional methods of cancer detection using odor. *TrAC Trends Anal Chem*. 2012;38:1–12. Available from: <https://doi.org/10.1016/j.trac.2012.03.019>.

## Breast cancer

### 2018

Phillips M, Cataneo RN, Cruz-Ramos JA, Huston J, Ornelas O, Pappas N, et al. Prediction of breast cancer risk with volatile biomarkers in breath. *Breast Cancer Res Treat.* 2018;170(2):343-350. Available from: doi: 10.1007/s10549-018-4764-4.

### **2017**

Phillips M, Cataneo RN, Lebauer C, Mundada M, Saunders C. Breath mass ion biomarkers of breast cancer. *J Breath Res.* 2017;11:016004. Available from: doi: 10.1088/1752-7163/aa549b.

### **2014**

Phillips M, Beatty JD, Cataneo RN, Huston J, Kaplan PD, Lalising RI, et al. Rapid point-of-care breath test for biomarkers of breast cancer and abnormal mammograms. *PLoS One.* 2014;9(3):e90226. Available from: doi: 10.1371/journal.pone.0090226.

### **2011**

Shuster G, Gallimidi Z, Reiss AH, Dovgolevsky E, Billan S, Abdah-Bortnyak R, et al. Classification of breast cancer precursors through exhaled breath. *Breast Cancer Res Treat.* 2011;126(3):791-6. Available from: doi: 10.1007/s10549-010-1317-x.

### **2010**

Phillips M, Cataneo RN, Saunders C, Hope P, Schmitt P, Wai J. Volatile biomarkers in the breath of women with breast cancer. *J Breath Res.* 2010;4(2):026003. Available from: doi: 10.1088/1752-7155/4/2/026003.

## **Colorectal cancer**

### **2014**

de Boer NK, de Meij TG, Oort FA, Ben Larbi I, Mulder CJ, van Bodegraven AA, et al. The scent of colorectal cancer: detection by volatile organic compound analysis. *Clin Gastroenterol Hepatol.* 2014;12(7):1085–9. Available from: doi: 10.1016/j.cgh.2014.05.005.

### **2013**

Altomare DF, Di Lena M, Procelli F, Trizio L, Travaglio E, Tutino M, et al. Exhaled volatile organic compounds identify patients with colorectal cancer. *Br. J. Surg.* 2013;100(1):144–50. Available from: doi: 10.1002/bjs.8942.

## **Gastric cancer**

### **2016**

Amal H, Leja M, Funka K, Skapars R, Sivins A, Ancans G, et al. Detection of precancerous gastric lesions and gastric cancer through exhaled breath. *Gut.* 2016;65(3):400–7. Available from: doi: 10.1136/gutjnl-2014-308536.

## **Gastric cancer**

### **2013**

Xu ZQ, Broza YY, Ionsecu R, Tisch U, Ding L, Liu H, et al. A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions. *Br J Cancer.* 2013;108(4):941–50. Available from: doi: 10.1038/bjc.2013.44.

## **Head-and-neck cancer**

**2011**

Hakim M, Billan S, Tisch U, Peng G, Dvrokkind I, Marom O, et al. Diagnosis of head-and-neck cancer from exhaled breath. *Br J Cancer.* 2011;104(10):1649–55. Available from: doi: 10.1038/bjc.2011.128.

**Lung cancer****2015**

Phillips M, Bauer TL, Cataneo RN, Lebauer C, Mundada M, Pass HI, et al. Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening. *PLoS One.* 2015;23;10(12):e0142484. Available from: doi: 10.1371/journal.pone.0142484.

**2014**

Bikov A, Hernadi M, Korosi BZ, Kunos L, Zsamboki G, Sutto Z, et al. Expiratory flow rate, breath hold and anatomic dead space influence electronic nose ability to detect lung cancer. *BMC Pulm Med.* 2014;14:202. Available from: doi: 10.1186/1471-2466-14-202.

Filipiak W, Filipiak A, Sponring A, Schmid T, Zelger B, Ager C, et al. Comparative analyses of volatile organic compounds (VOCs) from patients, tumors and transformed cell lines for the validation of lung cancer-derived breath markers. *J Breath Res.* 2014;8(2):027111. Available from: doi: 10.1088/1752-7155/8/2/027111.

Peled N, Abud-Hawa M, Liran O, Ilouze M, Gai-Mor N, Shlomi D, et al. Breath analysis as a noninvasive biomarker for early detection of lung cancer. *J Clin Oncol.* 2014;32 suppl:7560.

**2013**

Bos LD, van Walree IC, Kolk AH, Janssen HG, Sterk PJ, Schultz MJ. Alterations in exhaled breath metabolite-mixtures in two rat models of lipopolysaccharide-induced lung injury. *J Appl Physiol (1985).* 2013;115(10):1487–95. Available from: doi: 10.1152/japplphysiol.00685.2013.

Broza YY, Kremer R, Tisch U, Gevorkyan A, Shiban A, Best LA, et al. A nanomaterial-based breath test for short-term follow-up after lung tumor resection. *Nanomedicine.* 2013;9(1):15–21. Available from: doi: 10.1016/j.nano.2012.07.009.

**2012**

Hakim M, Broza YY, Barash O, Peled N, Phillips M, Amann A, et al. Volatile organic compounds of lung cancer and possible biochemical pathways. *Chem Rev.* 2012;112(11):5949–66. Available from: doi: 10.1021/cr300174a.

Wang Y, Hu Y, Wang D, Yu K, Wang L, Zou Y, et al. The analysis of volatile organic compounds biomarkers for lung cancer in exhaled breath, tissues and cell lines. *Cancer Biomark.* 2012;11(4):129–37. Available from: doi: 10.3233/CBM-2012-00270.

**2010**

Filipiak W, Sponring A, Filipiak A, Ager C, Schubert J, Miekisch W, et al. TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro. *Cancer Epidemiol Biomarkers Prev.* 2010;19(1):182–95. Available from: doi: 10.1158/1055-9965.EPI-09-0162.

Kischkel S, Miekisch W, Sawacki A, Straker EM, Trefz P, Amann A, et al. Breath biomarkers for lung cancer detection and assessment of smoking related effects—confounding variables, influence of normalization and statistical algorithms. *Clin Chim Acta.* 2010;411(21-22):1637–44. Available from: doi: 10.1016/j.cca.2010.06.005.

Poli D, Goldoni M, Corradi M, Acampa O, Carbognani P, Internullo E, et al. Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC/MS. *J. Chromatogr B.* 2010;878(27):2643–51. Available from: doi: 10.1016/j.jchromb.2010.01.022.

Fuchs P, Loesken C, Schubert JK, Miekisch W. Breath gas aldehydes as biomarkers of lung cancer. *Intl J Cancer.* 2010;126(11):2663–70. Available from: doi: 10.1002/ijc.24970.

### **Mesothelioma**

**2012**

Chapman EA, Thoma PS, Stone E, Lewis C, Yate DH. A breath test for malignant mesothelioma using an electronic nose. *Eur Respir J.* 2012;40(2):448–54. Available from: doi: 10.1183/09031936.00040911.

### **Oesophageal cancer**

**2018**

Chin S-T, Romano A, Sophie L. F. Doran SLF, Hanna GB. Cross-platform mass spectrometry annotation in breathomics of oesophageal-gastric cancer. *Sci Rep.* 2018;8(1):5139. Available from: doi: 10.1038/s41598-018-22890-w.

Kumar S, Huang J, Abbassi-Ghadi N, Mackenzie HA, Veselkov KA, Hoare JM, et al. Mass spectrometric analysis of exhaled breath for the identification of volatile organic compound biomarkers in esophageal and gastric adenocarcinoma. *Ann Surg.* 2015;262,981–90. Available from: doi: 10.1097/SLA.0000000000001101.

Kumar, S, Huang J, Abbassi-Ghadi N, Spanel P, Smith D, Hanna GB. Selected ion flow tube mass spectrometry analysis of exhaled breath for volatile organic compound profiling of esophago-gastric cancer. *Anal Chem.* 2013;85(12):6121–8. Available from: doi: 10.1021/ac4010309.

Markar SR, Lagergren J, Hanna GB. Research protocol for a diagnostic study of non-invasive exhaled breath analysis for the prediction of oesophago-gastric cancer. *BMJ Open.* 2016;6:e009139. Available from: doi: 10.1136/bmjopen-2015-009139.

### **Ovarian cancer**

**2015**

Kahn N, Lavie O, Paz M, Segev Y, Haick H. Dynamic nanoparticle-based flexible sensors: diagnosis of ovarian carcinoma from exhaled breath. *Nano Lett.* 2015;15(10):7023–8. Available from: doi: 10.1021/acs.nanolett.5b03052.

### **Pancreatic cancer**

**2018**

Arasaratnam RP, Wicaksono A, O'Brien H, Kocher HM, Covington JA, Crnogorac-Jurcevic T. Noninvasive diagnosis of pancreatic cancer through detection of volatile

organic compounds in urine. *Gastroenterol.* 2018;154(3):485-7. Available from: doi: 10.1053/j.gastro.2017.09.054.

### **Prostate cancer**

**2010**

Peng, G. Hakim M, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A, et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. *Br J Cancer.* 2010;103(4):542–51. Available from: doi: 10.1038/sj.bjc.6605810.

### **Chemical Sensibility Disorder**

**2013**

Mazzatorta A, Pokorski M, Cozzutto S, Barbieri P, Veratti V, Di Giulio C. Non-invasive assessment of exhaled breath pattern in patients with multiple chemical sensitivity disorder. *Adv Exp Med Biol.* 2013;756:179–88. Available from: doi: 10.1007/978-94-007-4549-0\_23.

### **Cystic Fibrosis**

**2015**

Shestivska V, Dryahina K, Nunvář J, Sovová K, Elhottová D, Nemec A, et al. Quantitative analysis of volatile metabolites released in vitro by bacteria of the genus *Stenotrophomonas* for identification of breath biomarkers of respiratory infection in cystic fibrosis. *J Breath Res.* 2015;9(2):027104. Available from: doi: 10.1088/1752-7155/9/2/027104.

**2014**

Whiteson KL, Meinardi S, Lim YW, Schmieder R, Maughan H, Quinn R, et al. Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation. *ISME J.* 2014;8:1247–58. Available from: doi: 10.1038/ismej.2013.229.

**2012**

Montuschi P, Paris D, Melck D, Lucidi V, Ciabattoni G, Raia V, et al. NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis. *Thorax.* 2012;67(3):222-8. Available from: doi: 10.1136/thoraxjnl-2011-200072.

**2011**

Colombo C, Faelli N, Tirelli AS, Fortunato F, Biffi A, Claut L, et al. Analysis of inflammatory and immune response biomarkers in sputum and exhaled breath condensate by a multi-parametric biochip array in cystic fibrosis. *Int J Immunopathol Pharmacol.* 2011;24(2):423–32.

### **Cytokines**

**2015**

Boshuizen M, Leopold JH, Zakharkina T, Knobel HH, Weda H, Nijssen TM, et al. Levels of cytokines in broncho-alveolar lavage fluid, but not in plasma, are associated with levels of markers of lipid peroxidation in breath of ventilated ICU patients. *J Breath Res.* 2015;9(3):036010. Available from: doi: 10.1088/1752-7155/9/3/036010.

**2010**

Antus B, Barta I, Czebe K, Horvath I, Csiszer E. Analysis of cytokine pattern in exhaled breath condensate of lung transplant recipients with bronchiolitis obliterans syndrome. *Inflamm Res* 2010;59(1):83–6.

### **Diabetes**

**2013**

Ghimenti S, Tabucchi S, Lomonaco T, Di Francesco F, Fuoco R, Onor M, et al. Monitoring breath during oral glucose tolerance tests. *J Breath Res*. 2013;7(1):017115. Available from: doi: 10.1088/1752-7155/7/1/017115.

Mazzatorta, A., Pokorski, M., Di Giulio, C. Real-time breath analysis in type 2 diabetes mellitus patients during cognitive effort. *Adv Exp Med Biol*. 2013;788:247-53. Available from: doi: 10.1007/978-94-007-6627-3\_35.

Yan K, Zhang D, Wu D, Wei H, Lu G. Design of a breath analysis system for diabetes screening and blood glucose level prediction. *IEEE Trans Biomed Eng*. 2014;61(11):2787-95. Available from: doi: 10.1109/TBME.2014.2329753.

### **Environmental Health Science**

**2016**

Pelclova D, Zdimal V, Kacer P, Fenclova Z, Vlckova S, Syslova K, et al. Oxidative stress markers are elevated in exhaled breath condensate of workers exposed to nanoparticles during iron oxide pigment production. *J Breath Res*. 2016;10(1):016004. Available from: doi: 10.1088/1752-7155/10/1/016004.

**2011**

Piel JD, Stiegel MA, Sobus UR. Breath biomarkers in environmental health science: exploring patterns in the human exposome. *J Breath Res*. 2011;5(4):046005. Available from: doi: 10.1088/1752-7155/5/4/046005.

### **Exhaled Breath Condensate**

**2015**

Moritz F, Janicka M, Zypler A, Forcisi S, Kot-Wasik A, Kot J, et al. The compositional space of exhaled breath condensate and its link to the human breath volatileome. *J Breath Res*. 2015;9(2):027105. Available from: doi: 10.1088/1752-7155/9/2/027105.

**2014**

Bikov A, Galffy G, Tamasi L, Bartusek D, Antus B, Losonczy G, et al. Exhaled breath condensate pH decreases during exercise-induced bronchoconstriction. *Respirology*. 2014;19(4):563–9. Available from: doi: 10.1111/resp.12248.

**2012**

Effros RM, Casaburi R, Porszasz J, Morales EM, Rehan V. Exhaled breath condensates: analyzing the expiratory plume. *Am J Respir Crit Care Med*. 2012;185(8):803–4.

**2010**

Marek EM, Volke J, Hawener I, Platen P, Mückenhoff K, Marek W. Measurements of lactate in exhaled breath condensate at rest and after maximal exercise in young and healthy subjects. *J Breath Res*. 2010;4(1):017105. Available from: doi: 10.1088/1752-7155/4/1/017105.

Lázár Z, Vass G, Huszár É, Losonczy G, Horvath I. Exhaled breath condensate: adenosine, ATP and other purines. *Eur Respir Mon.* 2010;49:183–95. Available from: doi: 10.1183/1025448x.00019209.

Reinhold P, Knobloch H. Exhaled breath condensate: lessons learned from veterinary medicine. *J Breath Res.* 2010;4(1):017001. Available from: doi: 10.1088/1752-7155/4/1/017001.

### **Exhaled Particles**

#### **2015**

Schwarz K, Biller H, Windt H, Koch W, Hohlfeld JM. Characterization of exhaled particles from the human lungs in airway obstruction. *J Aerosol Med Pulm Drug Deliv.* 2015;28:52–8. Available from: doi: 10.1089/jamp.2013.1104.

#### **2013**

Bredberg A, Josefson M, Almstrand AC, Lausmaa J, Sjövall P, Levinsson A, et al. Comparison of exhaled endogenous particles from smokers and non-smokers using multivariate analysis. *Respiration.* 2013;86(2):135–42. Available from: doi: 10.1159/000350941.

Holmgren H, Gerth E, Ljungström E, Larsson P, Almstrand AC, Bake B, et al. Effects of breath holding at low and high lung volumes on amount of exhaled particles. *Respir Physiol Neurobiol.* 2013;185(2):228–34. Available from: doi: 10.1016/j.resp.2012.10.010.

#### **2012**

Bredberg A, Gobom J, Almstrand AC, Larsson P, Blennow K, Olin AC, et al. Exhaled endogenous particles contain lung proteins. *Clin Chem.* 2012;58(2):431–40. Available from: doi: 10.1373/clinchem.2011.169235.

Larsson P, Mirgorodskaya E, Samuelsson L, Bake B, Almstrand AC, Bredberg A, et al. Surfactant protein A and albumin in particles in exhaled air. *Resp Med.* 2012;106(2):197–204. Available from: doi: 10.1016/j.rmed.2011.10.008.

#### **2010**

Almstrand AC, Bake B, Ljungstrom E, Larsson P, Bredberg A, Mirgorodskaya E, et al. Effect of airway opening on production of exhaled particles. *J Appl Physiol (1985).* 2010;108(3):584–8. Available from: doi: 10.1152/japplphysiol.00873.2009.

Schwarz K, Biller H, Windt H, Koch W, Hohlfeld JM. Characterization of exhaled particles from the healthy human lung-a systematic analysis in relation to pulmonary function variables. *J Aerosol Med Pulm Drug Delivery.* 2010;23(6):371–9. Available from: doi: 10.1089/jamp.2009.0809.

### **Forensics**

#### **2015**

Kwak J, Geier BA, Fan M, Rinehardt SA, Watts BS, Grigsby CC, et al. Detection of volatile organic compounds indicative of human presence in the air. *J Sep Sci.* 2015;38(14):2463–9. Available from: doi: 10.1002/jssc.201500261.

**Gastric Emptying****2015**

Bharucha A, Batey-Schaefer B, Cleary PA, et al. Delayed gastric emptying is associated with early and long-term hyperglycemia in Type 1 diabetes mellitus. *Gastroenterology*. 2015;149(2):330-9. Available from: doi: 10.1053/j.gastro.2015.05.007.

**2013**

Bharucha AE, Camilleri M, Veil E, Burton D, Zinsmeister AR. Comprehensive assessment of gastric emptying with a stable isotope breath test. *Neurogastroenterol Motil.* 2013;25(1):e60–e69. Available from: doi: 10.1111/nmo.12054.

**Heart Failure****2012**

Voss A, Witt K, Fischer C, Reulecke S, Poitz W, Kechagias V, et al. Smelling heart failure from human skin odor with an electronic nose. *Conf Proc IEEE Eng Med Biol Soc.* 2012;2012:4034–7. Available from: doi: 10.1109/EMBC.2012.6346852.

**2010**

Curran AM, Prada PA, Furton KG. The differentiation of the volatile organic signatures of individuals through SPME-GC/MS of characteristic human scent compounds. *J Forensic Sci.* 2010;55(1):50–7. Available from: doi: 10.1111/j.1556-4029.2009.01236.x.

**Inflammatory Bowel Disease****2016**

Rieder F, Kurada S, Grove D, Cikach F, Lopez R, Patel N, et al. A distinct colon-derived breath metabolome is associated with inflammatory bowel disease, but not its complications. *Clin Transl Gastroenterol.* 2016;7(11):e201. Available from: doi: 10.1038/ctg.2016.57.

**2015**

Bodelier AG, Smolinska A, Baranska A, Dallinga JW, Mujagic Z, Vanhees K, et al. Volatile organic compounds in exhaled air as novel marker for disease activity in Crohn's disease: a metabolomic approach. *Inflamm Bowel Dis.* 2015;21(8):1776–85. Available from: doi: 10.1097/MIB.0000000000000436.

Hicks LC, Huang J, Kumar S, Powles ST, Orchard TR, Hanna GB, et al. Analysis of exhaled breath volatile organic compounds in inflammatory bowel disease: a pilot study. *J Crohns Colitis.* 2015;9(9):731–7. Available from: doi: 10.1093/ecco-jcc/jjv102.

**Infectious Diseases****2015**

van der Schee MP, Hashimoto S, Schuurman AC, van Driel JS, Adriaens N, van Amelsvoort RM, et al. Altered exhaled biomarker profiles in children during and after rhinovirus-induced wheeze. *Eur Respir J.* 2015;45(2):440–8. Available from: doi: 10.1183/09031936.00044414.

**2014**

Boots AW, Smolinska A, van Berkel JJ, Fijten RR, Stobberingh EE, Boumans ML, et al.

Identification of microorganisms based on headspace analysis of volatile organic compounds by gas chromatography-mass spectrometry. *J Breath Res.* 2014;8(2):027106. Available from: doi: 10.1088/1752-7155/8/2/027106.

### **Helicobacter pylori**

**2010**

Atreja A, Fu AZ, Sanaka MR, Vargo JJ. Non-invasive testing for Helicobacter pylori in patients hospitalized with peptic ulcer haemorrhage: a cost-effectiveness analysis. *Dig Dis Sci.* 2010;55(5):1356–63. Available from: doi: 10.1007/s10620-009-0865-6.

### **Influenza**

**2010**

Phillips M, Cataneo RN, Chaturvedi A, Danaher PJ, Devadiga A, Legendre DA, et al. Effect of influenza vaccination on oxidative stress products in breath. *J Breath Res.* 2010;4(2):026001. Available from: doi: 10.1088/1752-7155/4/2/026001.

### **Malaria**

**2012**

Wong RPM, Flematti GR, Davis TM. Investigation of volatile organic biomarkers derived from Plasmodium falciparum in vitro. *Malar J.* 2012;11:314. Available from: doi: 10.1186/1475-2875-11-314.

### **Tuberculosis**

**2012**

Phillips M, Basa-Dalay V, Blais J, Bothamley G, Chaturvedi A, Modi KD, et al. Point-of-care breath test for biomarkers of active pulmonary tuberculosis. *Tuberculosis (Edinb).* 2012;92(4):314-20. Available from: doi: 10.1016/j.tube.2012.04.002.

**2010**

Phillips M, Basa-Dalay V, Bothamley G, et al. Breath biomarkers of active pulmonary tuberculosis. *Tuberculosis (Edinb).* 2010;90(2):145-51. Available from: doi: 10.1016/j.tube.2010.01.003.

### **Liver Disease**

**2015**

Alkhouri N, Singh T, Alsabbagh E, et al. Isoprene in the exhaled breath is a novel biomarker for advanced fibrosis in patients with chronic liver disease: a pilot study. *Clin Transl Gastroenterol.* 2015;6:e112.

Eng K, Alkhouri N, Cikach F, Guirguis J, Chami T, Hanouneh I, et al. Analysis of breath volatile organic compounds in children with chronic liver disease compared to healthy controls. *J Breath Res.* 2015;9:026002. Available from: doi: 10.1038/ctg.2015.40.

Fernandez Del Rio R, O'Hara ME, Holt A, Pemberton P, Shah T, Whitehouse T, et al. Volatile biomarkers in breath associated with liver cirrhosis—comparisons of pre- and post-liver transplant breath samples. *EBioMedicine.* 2015;2(9):1243–50. Available from: doi: 10.1016/j.ebiom.2015.07.027.

### **NITRIC OXIDE TESTING**

**2015**

Jacinto T, Malinovschi A, Janson C, Fonseca J, Alving K. Evolution of exhaled nitric oxide levels throughout development and aging of healthy humans. *J Breath Res.* 2015;9(3):036005. Available from: doi: 10.1088/1752-7155/9/3/036005.

### 2014

Berhane K, Zhang Y, Salam MT, Eckel SP, Linn WS, Rappaport EB, et al. Longitudinal effects of air pollution on exhaled nitric oxide: the Children's Health Study. *Occup Environ Med.* 2014;71:507–13. Available from: doi: 10.1136/oemed-2013-101874.

Eckel SP, Linn WS, Berhane K, Rappaport EB, Salam MT, Zhang Y, et al. Estimation of parameters in the two-compartment model for exhaled nitric oxide. *PLoS One.* 2014;9(1):e85471. Available from: doi: 10.1371/journal.pone.0085471.

Haccuria A, Michils A, Michiels S, Van Muylem A. Exhaled nitric oxide: a biomarker integrating both lung function and airway inflammation changes. *J Allergy Clin Immunol.* 2014;134(3):554–9. Available from: doi: 10.1016/j.jaci.2013.12.1070.

Högman M, Thordadsson A, Hedenstierna G, Meriläinen P. A practical approach to the theoretical models to calculate NO parameters of the respiratory system. *J Breath Res.* 2014;8(1):016002. Available from: doi: 10.1088/1752-7155/8/1/016002.

Saito J, Gibeon D, Macedo P, Menzies-Gow A, Bhavsar PK, Chung KF. Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control. *Eur Respir J.* 2014;43(2):474–84. Available from: doi: 10.1183/09031936.00048513.

### 2013

Cattoni I, Guarnieri G, Tosetto A, Mason P, Scarpa MC, Saetta M, et al. Mechanisms of decrease in fractional exhaled nitric oxide during acute bronchoconstriction. *Chest.* 2013;143(5):1269–76. Available from: doi: 10.1378/chest.12-1374.

Cristescu SM, Mandon J, Harren FJ, Meriläinen P, Högman M. Methods of NO detection in exhaled breath. *J Breath Res.* 2013;7(1):017104. Available from: doi: 10.1088/1752-7155/7/1/017104.

Leigh MW, Hazucha MJ, Chawla KK, Baker BR, Shapiro AJ, Brown DE, et al. Standardizing nasal nitric oxide measurement as a test for primary ciliary dyskinesia. *Ann Am Thorac Soc.* 2013;10(6):574–81. Available from: doi: 10.1513/AnnalsATS.201305-110OC.

### 2012

Högman M. Extended NO analysis in health and disease. *J Breath Res.* 2012;6(4):047103. Available from: doi: 10.1088/1752-7155/6/4/047103.

Piirila P, Rouhos A, Kainu A, Sovijärvi AR. Reduction of fractional exhaled nitric oxide (FENO) and its variation by mouth wash. *Scand J Clin Lab Invest.* 2012;72(3):253–7. Available from: doi: 10.3109/00365513.2012.658437.

### 2011

Marthin JK, Nielsen KG. Choice of nasal nitric oxide technique as first-line test for primary ciliary dyskinesia. *Eur Respir J.* 2011;37(3):559–65. Available from: doi: 10.1183/09031936.00032610.

Taylor DR, Palmary R, Cowan JO, Herbison GP. Long term performance characteristics of an electrochemical nitric oxide analyser. *Respir Med.* 2011;105(2):211–7. Available from: doi: 10.1016/j.rmed.2010.09.001.

### **Parkinson's Disease**

**2019**

Trivedi DK, Sinclair E, Xu Y, Sarkar D, Walton-Doyle C, Liscio C, Banks P, Milne J, Silverdale M, Kunath T, Goodacre R, Barran P. Discovery of volatile biomarkers of Parkinson's Disease from sebum. *ACS Cent Sci.* 2019. Available from: <https://pubs.acs.org/doi/10.1021/acscentsci.8b00879>.

**2015**

Nakhleh MK, Badarny S, Winer R, Jeries R, Finberg J, Haick H. Distinguishing idiopathic Parkinson's disease from other parkinsonian syndromes by breath test. *Parkinsonism Relat Disord.* 2015;21(2):150–3. Available from: doi: 10.1016/j.parkreldis.2014.11.023.

### **Pregnancy**

**2011**

Bikov A, Pako J, Kovacs D, Tamasi L, Lazar Z, Rigo J, et al. Exhaled breath volatile alterations in pregnancy assessed with electronic nose. *Biomarkers.* 2011;16(6):476–84. Available from: doi: 10.3109/1354750X.2011.598562.

### **Pulmonary Disease**

**2018**

van Oort PM, Povoa P, Schnabel R, Dark P, Artigas A, Bergmans DCJJ, et al. The potential role of exhaled breath analysis in the diagnostic process of pneumonia-a systematic review. *J Breath Res.* 2018;12:024001. Available from: doi: 10.1088/1752-7163/aaa499.

**2017**

Nakhleh MK, Haick H, Humbert M, Cohen-Kaminsky S. Volatolomics of breath as an emerging frontier in pulmonary arterial hypertension. *Eur Respir J.* 2017;49(2):1601897. Available from:

**2015**

Antonelli Incalzi R, Pennazza G, Scarlata S, Santonico M, Vernile C, Cortese L, et al. Comorbidity modulates non invasive ventilation-induced changes in breath print of obstructive sleep apnea syndrome patients. *Sleep Breath.* 2015;19(2):623–30. Available from: doi: 10.1007/s11325-014-1065-y.

Besa V, Teschler H, Kurth I, Khan AM, Zarogoulidis P, Baumbach JI, et al. Exhaled volatile organic compounds discriminate patients with chronic obstructive pulmonary disease from healthy subjects. *Int J Chron Obstruct Pulmon Dis.* 2015;10:399–406. Available from: doi: 10.2147/COPD.S76212.

Dragonieri S, Porcelli F, Longobardi F, Carratù P, Aliani M, Ventura VA, et al. An electronic nose in the discrimination of obese patients with and without obstructive sleep apnoea. *J Breath Res.* 2015;9(2):026005. Available from: doi: 10.1088/1752-7155/9/2/026005.

Kunos L, Bikov A, Lazar Z, Korosi BZ, Benedek P, Losonczy G, et al. Evening and morning exhaled volatile compound patterns are different in obstructive sleep apnoea assessed with electronic nose. *Sleep Breath*. 2015;19(1):247–53. Available from: doi: 10.1007/s11325-014-1003-z.

Figueroa JA, Mansoor JK, Allen RP, Davis CE, Walby WF, Aksенов AA, et al. Exhaled volatile organic compounds in individuals with a history of high altitude pulmonary edema and varying hypoxia-induced responses. *J Breath Res*. 2015;9(2):026004. Available from: doi: 10.1088/1752-7155/9/2/026004.

van der Schee MP, Paff T, Brinkman P, van Aalderen WM, Haarman EG, Sterk PJ. Breathomics in lung disease. *Chest*. 2015;147(1):224–31. Available from: doi: 10.1378/chest.14-0781.

#### 2014

Bjermer L, Alving K, Diamant Z, Magnussen H, Pavord I, Piacentini G, et al. Current evidence and future research needs for FeNO measurement in respiratory diseases. *Respir Med*. 2014;108(6):830–41. Available from: doi: 10.1016/j.rmed.2014.02.005.

Bos LD, Schultz MJ, Sterk PJ. Exhaled breath profiling for diagnosing acute respiratory distress syndrome. *BMC Pulm Med*. 2014;14:72. Available from: doi: 10.1186/1471-2466-14-72.

Bos LD, Weda H, Wang Y, Knobel HH, Nijesen TM, Vink TJ, et al. Exhaled breath metabolomics as a noninvasive diagnostic tool for acute respiratory distress syndrome. *Eur Respir J*. 2014;44:188–97. Available from: doi: 10.1183/09031936.00005614.

Sibila O, Garcia-Bellmunt L, Giner J, Merino JL, Suarez-Cuartin G, Torrego A, et al. Identification of airway bacterial colonization by an electronic nose in chronic obstructive pulmonary disease. *Respir Med*. 2014;108(11):1608–14. Available from: doi: 10.1016/j.rmed.2014.09.008.

#### 2013

Benedek P, Lázár Z, Bikov A, Kunos L, Katona G, Horváth I. Exhaled biomarker pattern is altered in children with obstructive sleep apnoea syndrome. *Int J Pediatr Otorhinolaryngol*. 2013;77(8):1244–7. Available from: doi: 10.1016/j.ijporl.2013.04.025.

Cohen-Kaminsky S, Nakhleh M, Perros F, Montani D, Girerd B, Garcia G, et al. A proof of concept for the detection and classification of pulmonary arterial hypertension through breath analysis with a sensor array. *Am J Respir Crit Care Med*. 2013(6);188:756–9. Available from: doi: 10.1164/rccm.201303-0467LE.

van de Kant KD, van Berkel JJ, Jobsis Q, Lima Passos V, Klaassen EM, van der Sande L, et al. Exhaled breath profiling in diagnosing wheezy preschool children. *Eur Respir J*. 2013;41(1):183–8. Available from: doi: 10.1183/09031936.00122411.

#### 2012

Basanta M, Ibrahim B, Dockry R, Douce D, Morris M, Singh D, et al. Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. *Respir Res* 2012;13:72. Available from: doi: 10.1186/1465-9921-13-72.

Incalzi RA, Pennazza G, Scarlata S, Santonico M, Petriaggi M, Chiurco D, et al. Reproducibility and respiratory function correlates of exhaled breath fingerprint in chronic obstructive pulmonary disease. *PLoS One*. 2012;7(10):e45396. Available from: doi: 10.1371/journal.pone.0045396.

### **Chronic Obstructive Pulmonary Disease (COPD) 2015**

Allers M, Langejuergen J, Gaida A, Holz O, Schuchardt S, Hohlfeld JM, et al. Measurement of exhaled volatile organic compounds from patients with chronic obstructive pulmonary disease (COPD) using closed gas loop GC-IMS and GC-APCI-MS. *J. Breath Res*. 2016;10(2):026004. Available from: doi: 10.1088/1752-7155/10/2/026004.

Essat M, Harnan S, Gomersall T, Tappenden P, Wong R, Pavord I, et al. Fractional exhaled nitric oxide for the management of asthma in adults: systematic review. *Eur Respir J*. 2016;47(3):751–68. Available from: doi: 10.1183/13993003.01882-2015.

Lärstad M, Almstrand A-C, Larsson P, Bake B, Larsson S, Ljungström E, et al. Surfactant protein A in exhaled endogenous particles is decreased in chronic obstructive pulmonary disease (COPD) patients: a pilot study. *PLoS One*. 2015;10(12):e0144463. Available from: doi: 10.1371/journal.pone.0144463.

### **2014**

Phillips C, Mac Parthalain N, Syed Y, Deganello D, Claypole T, Lewis K. Short-term intra-subject variation in exhaled volatile organic compounds (VOCs) in COPD patients and healthy controls and its effect on disease classification. *Metabolites*. 2014;4(2):300–18. Available from: doi: 10.3390/metabo4020300.

### **2013**

Fens N, van Rossum AG, Zanen P, van Ginneken B, van Klaveren RJ, Zwinderman AH, et al. Subphenotypes of mild-to-moderate COPD by factor and cluster analysis of pulmonary function, CT imaging and breathomics in a population-based survey. *COPD*. 2013;10(3):277–85. Available from: doi: 10.3109/15412555.2012.744388.

Basanta M, Ibrahim B, Dockry R, Douce D, Morris M, Singh D, et al. Exhaled volatile organic compounds for phenotyping chronic obstructive pulmonary disease: a cross-sectional study. *Respir Res*. 2012;13:72. Available from: doi: 10.1186/1465-9921-13-72.

### **2011**

Fens N, de Nijs SB, Peters S, Dekker T, Knobel HH, Vink TJ, et al. Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. *Eur Respir J*. 2011;38(6):1301-9. Available from: doi: 10.1183/09031936.00032911.

Papaioannou AI, Loukides S, Minas M, Kontogianni K, Bakakos P, Gourgoulianis KI, et al. Exhaled breath condensate pH as a biomarker of COPD severity in ex-smokers.

*Respir Res.* 2011;12:67. Available from: doi: 10.1186/1465-9921-12-67.

Sanak M, Gielicz A, Bochenek G, Kaszuba M, Niżankowska-Mogilnicka E, Szczechlik A. Targeted eicosanoid lipidomics of exhaled breath condensate provide a distinct pattern in the aspirin-intolerant asthma phenotype. *J Allergy Clin Immunol.* 2011;127(5):1141–7. Available from: doi: 10.1016/j.jaci.2010.12.1108.

Teng Y, Sun P, Zhang J, Yu R, Bai J, Yao X, et al. Hydrogen peroxide in exhaled breath condensate in patients with asthma: a promising biomarker? *Chest.* 2011;140(1):108–16. Available from: doi: 10.1378/chest.10-2816.

### 2010

Antus B, Barta I, Horvath I, Csiszer E. Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. *Respirology.* 2010;15(3):472–7. Available from: doi: 10.1111/j.1440-1843.2010.01711.x.

Van Berkel JJ, Dallinga JW, Moller GM, Godschalk RW, Moonen EJ, Wouters EF, et al. A profile of volatile organic compounds in breath discriminates COPD patients from controls. *Respir Med.* 2010;104(4):557–63. Available from: doi: 10.1016/j.rmed.2009.10.018.

### Pulmonary Embolism (PE)

#### 2010

Fens N, Douma RA, Sterk PJ, Kamphuisen PW. Breathomics as a diagnostic tool for pulmonary embolism. *J Thromb Haemost.* 2010;8(12):2831-3. Available from: doi: 10.1111/j.1538-7836.2010.04064.x.

### Systemic Sclerosis

#### 2010

Tufvesson E, Bozovic G, Hesselstrand R, Bjermer L, Scheja A, Wuttge DM. Increased cysteinyl-leukotrienes and 8-isoprostanate in exhaled breath condensate from systemic sclerosis patients. *Rheumatology (Oxford).* 2010;49(12):2322–6. Available from: doi: 10.1093/rheumatology/keq271.

### Therapeutic/Gamma Irradiation

#### 2015

Phillips M, Cataneo RN, Chaturvedi A, Kaplan PD, Libardoni M, Mundada M, et al. Breath biomarkers of whole-body gamma irradiation in the Gottingen minipig. *Health Phys.* 2015;108(5):538-46. Available from: doi: 10.1097/HP.0000000000000272.

#### 2013

Phillips M, Byrnes R, Cataneo RN, Chaturvedi A, Kaplan PD, Libardoni M, et al. Detection of volatile biomarkers of therapeutic radiation in breath. *J Breath Res.* 2013;7(3):036002. Available from: doi: 10.1088/1752-7155/7/3/036002.

Thrall KD, Murphy MK, Lovaglio J, Cataneo RN, Chaturvedi A, Mundada M, et al. A dose-dependent hematological evaluation of whole-body gamma-irradiation in the Gottingen minipig. *Health Phys.* 2013;105(3):245-52. Available from: doi: 10.1097/HP.0b013e31829253a1.

### Transplantation

**2013**

Kovacs D, Bikov A, Losonczy G, Murakozsy G, Horvath I. Follow up of lung transplant recipients using an electronic nose. *J Breath Res.* 2013;7(1):017117. Available from: doi: 10.1088/1752-7155/7/1/017117.

**Genetics**

Tarnoki DL, Bikov A, Tarnoki AD, Lazar Z, Szilagyi BK, Korosi BZ, et al. Lack of heritability of exhaled volatile compound pattern: an electronic nose twin study. *J Breath Res.* 2014;8(1):016001. Available from: doi: 10.1088/1752-7155/8/1/016001.

**Inflammation****2016**

Schleich FN, Dallinga JW, Henket M, Wouters EF, Louis R, Van Schooten FJ. Volatile organic compounds discriminate between eosinophilic and neutrophilic inflammation in vitro. *J Breath Res.* 2016;10(1):016006. Available from: doi: 10.1088/1752-7155/10/1/016006.

**5.3. PRACTICE GUIDELINE****2011**

Dweik RA, Boggs PB, Erzurum SC, et al., 2011. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. *Am Resp Crit Care Med.* 2011;184(5):60615. Available from: doi: 10.1164/rccm.9120-11ST.

**5.4. REVIEWS, BOOKS & OPINIONS****2019**

Hayton C, Terrington D, Wilson AM, Chaudhuri N, Leonard C, Fowler SJ. Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review. *Resp Res.* 2019;20:7. Available from: <https://doi.org/10.1186/s12931-019-0971-8>.

Jia Z, Patra A, Kutty VK, Venkatesan T. Critical review of volatile organic compound analysis in breath and in vitro cell culture for detection of lung cancer. *Metabolites.* 2019;9:5. Available from: <https://doi.org/10.3390/metabo9030052>.

Scarlata S, Incalzi RA. Breath analysis in respiratory diseases: state-of-the-art and future perspectives. *Exp Rev Mol Diagn.* 2019;19:47-61.

**2018**

Hanna GB, Boshier PR, Markar SR, Romano A. Accuracy and Methodologic Challenges of Volatile Organic Compound-Based Exhaled Breath Tests for Cancer Diagnosis: A Systematic Review and Meta-analysis. *JAMA Oncol.* 2018 Aug 16:e182815. Available from: doi: 10.1001/jamaoncology.2018.2815.

Hua Q, Zhu Y, Liu H. Detection of volatile organic compounds in exhaled breath to screen lung cancer: a systematic review. *Future Oncol.* 2018;14:1647-62. Available from: doi: 10.2217/fon-2017-0676.

**2017**

Ahmed WM, Lawal O, Nijzen TM, Goodacre R, Fowler SJ. Exhaled volatile organic compounds of infection: A systematic review. *ACS Infect Dis.* 2017;3(10):695–710. Available from: doi: 10.1021/acsinfecdis.7b00088.

Beale DJ, Jones OAH, Karpe AV, Dayalan S, Oh DY, Kouremenos KA, et al. A review of analytical techniques and their application in disease diagnosis in breathomics and salivaomics research. *Int J Mol Sci.* 2017;18(1):24. Available from: doi: 10.3390/ijms18010024.

Lawal O, Ahmed WM, Nijzen TME, Goodacre R, Fowler SJ. Exhaled breath analysis: a review of ‘breath-taking’ methods for off-line analysis. *Metabolomics.* 2017;13(10):110. Available from: doi: 10.1007/s11306-017-1241-8.

**2016**

Christiansen A, Davidsen JR, Titlestad I, Vestbo J, Baumbach J. A systematic review of breath analysis and detection of volatile organic compounds in COPD. *J Breath Res.* 2016;10(3):034002. Available from: doi: 10.1088/1752-7155/10/3/034002.

Rufo JC, Madureira J, Fernandes EO, Moreira A. Volatile organic compounds in asthma diagnosis: a systematic review and meta-analysis. *Allergy.* 2016;71(2):175–88. Available from: doi: 10.1111/all.12793.

**2015**

Broza YY, Mochalski P, Ruzsanyi V, Amann A. Hybrid volatolomics and disease detection. *Angew Chem Int Ed Engl.* 2015;54(38):11036–48. Available from: doi: 10.1002/anie.201500153.

Krilaviciute A, Heiss JA, Leja M, Kupcinskas J, Haick H, Brenner H. Detection of cancer through exhaled breath: a systematic review. *Oncotarget.* 2015;6(36):38643–57. Available from: doi: 10.18632/oncotarget.5938.

van Mastrigt E, de Jongste JC, Pijnenburg MW. The analysis of volatile organic compounds in exhaled breath and biomarkers in exhaled breath condensate in children – clinical tools or scientific toys? *Clin Exp Allergy.* 2015;45(7):1170–88. Available from: doi: 10.1111/cea.12454.

**2014**

Collins SA, Gove K, Walker W, Lucas JS. Nasal nitric oxide screening for primary ciliary dyskinesia: systematic review and meta-analysis. *Eur Respir J.* 2014;44(6):1589–99. Available from: doi: 10.1183/09031936.00088614.

de Lacy Costello B, Amann A, Al-Kateb H, Flynn C, Filipiak W, Khalid T, et al. A review of the volatiles from the healthy human body. *J Breath Res.* 2014;8(1):014001. Available from: doi: 10.1088/1752-7155/8/1/014001.

Di Natale C, Paolesse R, Martinelli E, Capuano R. Solid-state gas sensors for breath analysis: a review. *Anal Chim Acta.* 2014;824:1–17. Available from: doi: 10.1016/j.aca.2014.03.014.

Haick H, Broza YY, Mochalski P, Ruzsanyi V, Amann A. Assessment, origin, and implementation of breath volatile cancer markers. *Chem Soc Rev.* 2014;43(5):1423–49. Available from: doi: 10.1039/c3cs60329f.

Rattray NJ, Hamrang Z, Trivedi DK, Goodacre R, Fowler SJ. Taking your breath away: metabolomics breathes life in to personalized medicine. *Trends Biotechnol.* 2014;32(10):538–48. Available from: doi: 10.1016/j.tibtech.2014.08.003.

Smolinska A, Hauschild AC, Fijten RR, Dallinga JW, Baumbach J, van Schooten FJ. Current breathomics – a review on data pre-processing techniques and machine learning in metabolomics breath analysis. *J Breath Res.* 2014;8:027105. Available from: doi: 10.1088/1752-7155/8/2/027105.

### 2013

Alonso M, Sanchez JM. Analytical challenges in breath analysis and its application to exposure monitoring. *Trends Anal Chem.* 2013;44:78–89. Available from: doi: 10.1016/j.jchromb.2015.08.041.

Bos LD, Sterk PJ, Schultz MJ. Volatile metabolites of pathogens: a systematic review. *PLoS Pathog.* 2013;9(5):e1003311. Available from: doi: 10.1371/journal.ppat.1003311.

Broza YY, Haick H. Nanomaterial-based sensors for detection of disease by volatile organic compounds. *Nanomedicine (Lond).* 2013;8:785–806. Available from: doi: 10.2217/nnm.13.64.

Mazzatorta A, Di Giulio C, Pokorski M. Pathologies currently identified by exhaled biomarkers. *Respir Physiol Neurobiol.* 2013;187(1):128–34. Available from: doi: 10.1016/j.resp.2013.02.016.

Montuschi P, Mores N, Trove A, Mondino C, Barnes PJ. The electronic nose in respiratory medicine. *Respiration.* 2013;85(1):72–84. Available from: doi: 10.1159/000340044.

Pennazza G, Santonico M, Agro AF. Narrowing the gap between breathprinting and disease diagnosis, a sensor perspective. *Sens Actuators B Chem.* 2013;179:270–5. Available from: <https://doi.org/10.1016/j.snb.2012.09.103>.

Pleil JD, Stiegel MA. Evolution of environmental exposure science: using breath-borne biomarkers for “discovery” of the human exposome. *Anal Chem.* 2013;85(21):9984–90. Available from: doi: 10.1021/ac402306f.

Sethi S, Nanda R, Chakraborty T. Clinical application of volatile organic compound analysis for detecting infectious diseases. *Clin Microbiol Rev.* 2013;26(3):462–75. Available from: doi: 10.1128/CMR.00020-13.

Wheelock CE, Goss VM, Balgoma D, Nicholas B, Brandsma J, Skipp PJ, et al. Application of 'omics technologies to biomarker discovery in inflammatory lung diseases. *Eur Respir J.* 2013;42(3):802–25. Available from: doi: 10.1183/09031936.00078812.

**2012**

Boots AW, van Berkel JJ, Dallinga JW, Smolinska A, Wouters EF, van Schooten FJ. The versatile use of exhaled volatile organic compounds in human health and disease. *J Breath Res.* 2012;6(2):027108. Available from: doi: 10.1088/1752-7155/6/2/027108.

van de Kant KD, van der Sande LJ, Jobsis Q, van Schayck OC, Dompeling E. Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review. *Respir Res.* 2012;13:117. Available from: doi: 10.1186/1465-9921-13-117.

D'Amico A, Di Natale C, Falconi C, Martinelli E, Paolesse R, Pennazza G, et al. Detection and identification of cancers by the electronic nose. *Expert Opin Med Diagn.* 2012;6(3):175–85. Available from: doi: 10.1517/17530059.2012.665870.

**2011**

Koek MM, Jellema RH, van der Greef J, Tas AC, Hankemeier T. Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives. *Metabolomics.* 2011;7(3):307–28.

Shirasu M, Touhara K. The scent of disease: volatile organic compounds of the human body related to disease and disorder. *J Biochem.* 2011;150(3):257–66. Available from: doi: 10.1093/jb/mvr090.

**2010**

Horvath I, de Jongste JC, eds. Exhaled Biomarkers. European Respiratory Society Monograph, ERS:Sheffield, 2010.

**5.5. SPECIMENS, COLLECTION AND SAMPLING****2017**

Doran SL, Romano A, Hanna GB. Optimization of sampling parameters for standardized exhaled breath sampling. *J Breath Res.* 2017;12:016007. Available from: doi: 10.1088/1752-7163/aa8a46.

Sukul P, Oertel P, Kamysk S, Trefz P. Oral or nasal breathing? Real-time effects of switching sampling route onto exhaled VOC concentrations. *J Breath Res.* 2017;11(2):027101. Available from: doi: 10.1088/1752-7163/aa6368.

**2016**

Kang S, Thomas CLP. How long may a breath sample be stored for at -80 °C? A study of the stability of volatile organic compounds trapped onto a mixed Tenax:Carbograph trap adsorbent bed from exhaled breath. *J Breath Res.* 2016;10(2):026011. Available from: doi: 10.1088/1752-7155/10/2/026011.

**2015**

Sukul P, Trefz P, Kamysk S, Schubert JK, Miekisch W. Instant effects of changing body positions on compositions of exhaled breath. *J Breath Res.* 2015;9(4):047105. Available from: doi: 10.1088/1752-7155/9/4/047105.

**2014**

Bos LD, Wang Y, Weda H, Nijesen TM, Janssen AP, Knobel HH, et al. A simple breath sampling method in intubated and mechanically ventilated critically ill patients. *Respir Physiol Neurobiol.* 2014;191:67–74. Available from: doi: 10.1016/j.resp.2013.11.001.

Maurer F, Wolf A, Fink T, Rittershofer B, Heim N, Volk T, et al. Wash-out of ambient air contaminations for breath measurements. *J. Breath Res.* 2014;8(2):027107. Available from: doi: 10.1088/1752-7155/8/2/027107.

Pennazza G, Santonico M, Incalzi RA, Scarlata S, Chiurco D, Vernile C, et al. Measure chain for exhaled breath collection and analysis: a novel approach suitable for frail respiratory patients. *Sens Actuators B Chem.* 2014;204:578–87. Available from: <https://doi.org/10.1016/j.snb.2014.08.007>.

Sukul P, Trefz P, Schubert JK, Miekisch W. Immediate effects of breath holding maneuvers onto composition of exhaled breath. *J Breath Res.* 2014;8(3):037102. Available from: doi: 10.1088/1752-7155/8/3/037102.

### 2013

Beauchamp JD, Pleil JD. Simply breath-taking? Developing a strategy for consistent breath sampling. *J Breath Res.* 2013;7(4):042001. Available from: doi: 10.1088/1752-7155/7/4/042001.

Spanel P, Dryahina K, Smith D. A quantitative study of the influence of inhaled compounds on their concentration in exhaled breath. *J Breath Res.* 2013;7:017106. Available from: doi: 10.1088/1752-7155/7/1/017106.

### 2012

McKenzie JH, McDevitt JJ, Fabian MP, Hwang GM, Milton DK. Collection of aerosolized human cytokines using Teflon® filters. *PLoS One.* 2012;7(5):e35814. Available from: doi: 10.1371/journal.pone.0035814.

Rosias P. Methodological aspects of exhaled breath condensate collection and analysis. *J Breath Res.* 2012;6(2):027102. Available from: doi: 10.1088/1752-7155/6/2/027102.

### 2011

Boshier P, Priest OH, Hanna GB, Marcin N. Influence of respiratory variables on the on-line detection of exhaled trace gases by PTR-MS. *Thorax.* 2011;66(10):919–20. Available from: doi: 10.1136/thx.2011.161208.

Thekedar B, Oeh U, Szymczak W, Hoeschen C, Paretzke HG. Influences of mixed expiratory sampling parameters on exhaled volatile organic compound concentrations. *J Breath Res.* 2011;5(1):016001. Available from: doi: 10.1088/1752-7155/5/1/016001.

Boshier PR, Priest OH, Hanna GB, Marcin N. Influence of respiratory variables on the on-line detection of exhaled trace gases by PTR-MS. *Thorax.* 2011;66(10):919–20. Available from: doi: 10.1136/thx.2011.161208.

### 2010

Amann A, Miekisch W, Pleil J, Risby T, Schubert J. Methodological issues of sample collection and analysis of exhaled breath. In: Horvath I, de Jongste JC, editors. European Respiratory Monograph: *Exhaled Biomarkers.* 2010:96–114.

Koczulla AR, Noeske S, Herr C, Dette F, Pinkenburg O, Schmid S, et al. Ambient temperature impacts on pH of exhaled breath condensate. *Respirology*. 2010;15(1):155–9. Available from: doi: 10.1111/j.1440-1843.2009.01664.x.

Ohanian AS, Zimmerman J, Debley JS. Effects of sample processing, time and storage condition on cysteinyl leukotrienes in exhaled breath condensate. *J Breath Res*. 2010;4(4):046002. Available from: doi: 10.1088/1752-7155/4/4/046002.

Solga SF, Risby TH. What is normal breath? Challenge and opportunity. *IEEE Sens J*. 2010;10(4):7–9.

## **Concentrators**

**2018**

Lee SS. Breath analysis based on micropreconcentrator for early cancer diagnosis. *Proc SPIE* 10491, Microfluidics, BioMEMS, and Medical Microsystems XVI, 1049116 (19 February 2018); Available from: doi: 10.1117/12.2302380.

## **Confounding factors**

**2015**

Hauschild AC, Frisch T, Baumbach JI, Baumbach J. Carotta: revealing hidden confounder markers in metabolic breath profiles. *Metabolites*. 2015;5(2):344–63. Available from: doi: 10.3390/metabo5020344.

**2013**

Baranska A, Tigchelaar E, Smolinska A, Dallinga JW, Moonen EJ, Dekens JA, et al. Profile of volatile organic compounds in exhaled breath changes as a result of gluten-free diet. *J Breath Res*. 2013;7(3):037104. Available from: doi: 10.1088/1752-7155/7/3/037104.

Khalid TY, Saad S, Greenman J, de Lacy Costello B, Probert CS, Ratcliffe NM. Volatiles from oral anaerobes confounding breath biomarker discovery. *J Breath Res*. 2013;7(1):017114. Available from: doi: 10.1088/1752-7155/7/1/017114.

Pliel JD, Stiegel MA, Risby TH. Clinical breath analysis: discriminating between human endogenous compounds and exogenous (environmental) chemical confounders. *J Breath Res*. 2013;7(1):017107. Available from: doi: 10.1088/1752-7155/7/1/017107.

**2011**

Gajdoci R, Bikov A, Antus B, et al. Assessment of reproducibility of exhaled hydrogen peroxide concentration and the effect of breathing pattern in healthy subjects. *J Aerosol Med Pulm Drug Deliv* 2011;24:271–5.

## **Stability**

**2013**

Chen SF, Danao MG. Decomposition and solubility of H<sub>2</sub>O<sub>2</sub>: implications in exhaled breath condensate. *J Breath Res*. 2013;7(4):046001. Available from: doi: 10.1088/1752-7155/7/4/046001.

Mochalski P, King J, Unterkofler K, Amann A. Stability of selected volatile breath constituents in Tedlar, Kynar and Flexfilm sampling bags. *Analyst*. 2013;138(5):1405–18. Available from: doi: 10.1039/c2an36193k.

van der Schee MP, Fens N, Brinkman P, Bos LD, Angelo MD, Nijsen TM, et al. Effect of transportation and storage using sorbent tubes of exhaled breath samples on diagnostic accuracy of electronic nose analysis. *J Breath Res.* 2013;7(1):016002. Available from: doi: 10.1088/1752-7155/7/1/016002.

### **2012**

Bikov A, Galffy G, Tamasi L, Lazar Z, Losonczy G, Horvath I. Exhaled breath condensate pH is influenced by respiratory droplet dilution. *J Breath Res.* 2012;6(4):046002. Available from: doi: 10.1088/1752-7155/6/4/046002.

Effros RM, Casaburi R, Porszasz J, Morales EM, Saraswat A, Rehan V. Comment on 'the effect of temperature on exhaled breath condensate collection'. *J Breath Res.* 2012;6(4):048001; author reply 048002.

Kim YH, Kim KH, Jo SH, Jeon EC, Sohn JR, Parker DB. Comparison of storage stability of odorous VOCs in polyester aluminum and polyvinyl fluoride Tedlar® bags. *Anal Chim Acta.* 2012;712:162–7. Available from: doi: 10.1016/j.aca.2011.11.014.

Vyas A, Zhang Q, Gunaratne S, Lee W, Lin JL, Lin JS, et al. The effect of temperature on exhaled breath condensate collection. *J Breath Res.* 2012;6(3):036002. Available from: doi: 10.1088/1752-7155/6/3/036002.

### **Standardization**

#### **2017**

Doran SLF, Romano A, Hanna GB. Optimisation of sampling parameters for standardised exhaled breath sampling. *J Breath Res.* 2017;12(1):016007. Available from: doi: 10.1088/1752-7163/aa8a46.

#### **2015**

Hoffmeyer F, Berresheim H, Beine A, Sucker K, Brüning T, Bünger J. Methodological implications in pH standardization of exhaled breath condensate. *J Breath Res.* 2015;9(3):036003. Available from: doi: 10.1088/1752-7155/9/3/036003.

#### **2014**

Herbig J, Beauchamp J. Towards standardization in the analysis of breath gas volatiles. *J Breath Res.* 2014;8:037101. Available from: doi: 10.1088/1752-7155/8/3/037101.

### **Technical standards**

#### **2017**

Horváth I, Barnes PJ, Loukides S, Sterk PJ, Höglund M, Olin AC, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease. *Eur Respir J.* 2017;49(4):1600965. Available from: doi: 10.1183/13993003.00965-2016.

### **Validation**

#### **2015**

Boots AW, Bos LD, van der Schee MP, van Schooten FJ, Sterk PJ. Exhaled molecular fingerprinting in diagnosis and monitoring: Validating volatile promises. *Trends Mol Med.* 2015;21(10):633-44. Available from: doi: 10.1016/j.molmed.2015.08.001.